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Abstract
ROLE OF MITOCHONDRIAL BETA-OXIDATION IN ETHANOL
RESPONSE: A CANDIDATE GENE STUDY USING CAENORHABDITIS
ELEGANS
By Harini Pallikarana Tirumala
Master of Science in DNA Profiling from University of Central Lancashire, UK
2012
Directed by Jill C. Bettinger, Ph.D., Professor of Pharmacology and
Toxicology
Virginia Commonwealth University, 2017
Alcohol use disorder (AUD) is the fourth leading cause of preventable death in
the United States, and the fifth leading risk factor for premature death and
disability, globally. There are currently very few treatment options for AUD and
there is a need for effective preventive and treatment strategies for this
condition. AUD risk has a significant hereditary component, with the
contribution of genetic factors being estimated to be about 50%. The DaviesBettinger laboratory uses C. elegans as a model organism to study the
contribution of genetic factors in modulating neuronal responses to ethanol. In
this project, we examined the role of mitochondrial beta-oxidation of fatty
acids (FA) in altering ethanol responses using loss-of-function (lf) mutants and
RNAi-mediated knockdown of specific genes in this pathway. We tested a
total of 34 genes and found that lf in 13 genes significantly affected ethanol
response phenotypes. We conclude that mitochondrial beta-oxidation of FA is
essential for ethanol response behavior in C. elegans. Further experiments
need to be conducted to dissect the specific contribution of various
components of mitochondrial beta-oxidation in modifying the neuronal
responses to ethanol.
xvii

1. INTRODUCTION

1.1.

Alcoholism – National and Global Impact

“First you take a drink, then the drink takes a drink, then the drink takes you.”
~ F. Scott Fitzgerald
Alcohol is ranked among the top ten most addictive substances in the world
(Nutt et al., 2007). The National Institute on Alcohol Abuse and Alcoholism
(NIAAA) defines AUD as ‘problem drinking that becomes severe’. Medical
diagnosis of AUD requires an individual to meet at least 2 out of the 11 criteria
outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM),
within the same 12-month period. AUD can be classified as mild, moderate or
severe based on the number of criteria fulfilled.

According to the 2015 National Survey on Drug Use and Health (NSDUH),
15.1 million adults (18 years and older) in the United States had AUD and the
financial burden due to alcohol misuse in the US in 2010 was $249 billion.
While it is estimated that alcohol claims about 88,000 lives every year in the
US, in 2014 alone, alcohol-impaired driving fatalities accounted for 31% of
overall driving fatalities. With such a profound and significant impact on the
mortality and economy of the country, alcohol is the fourth leading
preventable cause of death in the United States. Statistics around the world
reflect a similar scenario with alcohol misuse being ranked as the fifth leading
risk factor for premature death and disability, globally (Alcohol facts and
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statistics, 2017). Specifically, about 25% of total deaths in the 20-39 years
age group are alcohol-attributable (WHO alcohol fact sheet, 2015).

Given the huge impact of alcohol abuse on individual and public health, global
economy and productivity, there is a need for effective prognostic, preventive
and therapeutic strategies to treat AUD. At present, the treatment for AUD is
largely focused on therapeutic counseling and other forms of behavioral
therapy. There are currently only three FDA approved drugs for treating
individuals suffering from AUD: Disulfiram, Naltrexone and Acamprosate
(Krishnan-Sarin et al., 2008). It is therefore important to invest in alcohol
research to identify effective prevention, management and treatment options
to curb the increasing rate of mortality associated with this debilitating
condition.

1.2.

Genetics of alcoholism

AUD is a multifactorial condition influenced by both environmental and genetic
factors, like most psychiatric and behavioral disorders. The contribution of
genetic factors to AUD risk has been estimated, by numerous family and twin
studies, to be in the range of 40-60% (Palmer et al., 2012), with the most
recent best-fit estimate being 49% (Verhulst et al., 2015). This is supported by
a multitude of molecular genetic studies that have identified several genetic
variants in candidate genes, which significantly influence the risk of
developing AUD. However, all of these variants put together only account for
a very small percentage of the genetic variance determined by the family
studies. Thus it is clear that there are multiple genes and genetic interactions
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that affect risk for AUD. This makes it a complex genetic condition to study,
even without taking into consideration the role of social and environmental
factors (Edenberg & Foroud, 2013).

Among the various negative effects of alcohol on human health, two of the
major areas of AUD research are physiological effects of alcohol metabolism
and the (direct) effects of alcohol on the brain and nervous system. Alcohol
dehydrogenase subunit beta (ADH1B) and aldehyde dehydrogenase 2
(ALDH2) are two enzymes are involved in ethanol metabolism. ADH1B
catalyzes the conversion of ethanol to acetaldehyde and the mitochondrial
ALDH2 is involved in the second step of this metabolism converting
acetaldehyde to acetate. Among genes that catalyze alcohol metabolism
(primarily in the liver), variants in ADH1B and ALDH2 are the most
significantly associated with risk of AUD (Tawa et al., 2016). Reactions
catalyzed by both these genes utilize NAD+ to produce NADH, altering the
NADH/NAD+ ratio within the cell. This increased NADH/NAD+ ratio inhibits
mitochondrial beta-oxidation of FA, as it is an allosteric regulator of this
pathway. Most of the acetate produced from the second reaction enters the
circulation and is metabolized to CO2 in heart, brain and skeletal muscle cells.
Acetate is also metabolized to acetyl CoA, which then enters metabolic
pathways such as ketone body production, amino acid and FA synthesis.
Acetate produced from acetaldehyde also enters the brain. Though the brain
primarily derives its energy from oxidation of glucose, the availability of
acetate, which requires fewer steps for oxidation and energy production,
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results in increased acetate uptake and decreased glucose utilization in the
brain.

Alcohol also exerts a wide range of effects on the central nervous system
(CNS) which can cause effects that include an increase in aggression,
reduced inhibition and impaired memory as it affects multiple pathways and
regions in the brain (M. Davies, 2003). The most prominent among these are
neurotransmitter-signaling pathways that affect the inhibitory and excitatory
systems in the brain (McIntosh & Chick, 2004). Genes in various
neurotransmitter-signaling pathways (particularly receptors) have been
implicated in AUD risk development. Some of the most widely researched
ones in this group include the γ-Aminobutyric acid (GABA) receptors, genes in
the serotonin, dopamine and glutamate pathways like the serotonintransporter-linked polymorphic region (5’-HTTLPR), dopamine receptor D2
(DRD2) (Banerjee, 2014) and glutamate metabotropic receptor 8 (GRM8)
respectively (Morozova et al., 2014). Despite extensive research, little is
known about the exact mechanisms of alcohol’s action on the nervous
system.

1.3.

Neuronal response to alcohol

AUD is a heterogeneous condition with a spectrum of clinical manifestations,
and several alcoholism typologies have been proposed to group together
affected individuals with a similar clinical course, in order to better predict their
response to treatment (Bogenschutz et al., 2009). Identifying genetic factors
associated with the condition is complex, probably due to this heterogeneous
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nature of AUD and the symptom-based diagnosis used (DSM criteria).
Therefore, scientists identified certain endophenotypes that can be used as
biomarkers and can be linked to specific genetic factors that could play a role
in development of AUD (Gottesman & Shields, 1973). An endophenotype is
any trait that is related to or part of a condition and might be influenced by a
small number of genes. It can be used to bridge the gap between biology of
the condition and its symptoms. In psychiatry research, a biomarker has to
fulfill the following criteria to be considered an endophenotype: it must
segregate with illness in the population and within families, must be heritable,
must not be state-dependent, must be present at a higher rate within affected
families than in the population, must be reliably measurable and specific to
the illness.

There are several established endophenotypes of AUD (Eng et al., 2005;
Salvatore et al., 2015). Level of response to alcohol is a reproducible and
well-characterized endophenotype, and it is commonly used in animal models
of alcohol research. Level of response can be defined as the ‘intensity of
response to alcohol at a specific Blood Alcohol Concentration (BAC)’
(Schuckit et al., 2011). It has been consistently shown that low level of
response (LR) to alcohol is a strong predictor of increased risk for AUD in the
future and that it is to an extent genetically influenced (Schuckit, 1980;
Schuckit, 1994). LR constitutes at least two components that are routinely
used in the lab, namely initial sensitivity (which refers to the level of
intoxication that appears soon after ethanol administration, when blood
ethanol levels are rising) and acute functional tolerance (AFT, the
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tolerance/adaptation of brain function developed within a single drinking
session, recorded at an equivalent concentration of alcohol on the declining
phase BAC relative to the rising phase BAC at initial sensitivity). These two
components have been successfully used to study the impact of genetic
factors on AUD in various invertebrate and vertebrate models (Engleman et
al., 2016; Morozova et al., 2014; Ponomarev & Crabbe, 2002).

1.3.1. Using C. elegans to study the molecular basis of neuronal response to
alcohol
Caenorhabditis elegans is a soil-dwelling, free-living nematode that has been
used as a model for research since early 1960s. Being the first multicellular
organism whose whole genome was sequenced, C. elegans is currently being
extensively used in research areas such as neuronal development, molecular
biology, genetics and developmental biology. Features like the ability to selffertilize (hermaphrodites) and mate with males, large brood size, short life
cycle, relatively small genome size (100.2Mb) and ease of genetic
manipulation (mutagenesis, RNA interference) make it an ideal model
organism for genetic studies. The primary reason for using C. elegans in
neuronal research is that its nervous system is simple but one of the most
extensively characterized among multicellular organisms, with a total of 302
neurons (in the adult hermaphrodite). Despite its small size, the C. elegans
nervous

system

is

complex

and

shares

most

of

the

mammalian

neurotransmitters, receptors and their molecular components. Among them
are serotonin, GABA, glutamate, dopamine and acetylcholine. Also, the basic
structural organization of neuron subtypes into sensory neurons, interneurons,
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and motor neurons is conserved between humans and C. elegans. The entire
wiring of neural circuits or the connectome of C. elegans was mapped by
John G. White in 1986, and this opened up the possibility of identifying the
functions of each individual neuron and its contribution to the nervous system.
C. elegans also exhibits complex behavioral traits (like chemo- and
mechanosensation, thermotaxis and avoidance of noxious stimuli) and
behavioral plasticity which makes it a useful model for neurobiology (Hobert,
2003).

Most behavioral studies in C. elegans utilize the change in locomotion pattern
in response to stimuli, as a measurable phenotype. Worms move by
undulatory propulsion; waves formed by the contraction and relaxation of
dorsal and ventral longitudinal body muscles travel along the length of the
body and allow forward propulsion (de Bono & Maricq, 2005). Motor behavior
is a trait that is predominantly under the control of the nervous system.
Therefore, effects on the nervous system are often displayed through
changes in motor behavior.

Neuronal responses to alcohol appear to be conserved in some invertebrates
including C. elegans (McIntire, 2005). Moreover, the intoxicating effects of
ethanol in C. elegans occur at similar concentrations as in mammals, which
make it an excellent model to study the effect of alcohol on the nervous
system. Behavioral responses to ethanol in humans include loss of social
inhibition and lack of coordination. Acute exogenous exposure to ethanol also
results in behavioral changes in C. elegans and these effects were found to
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be dose-dependent and reversible (A. Davies et al., 2003a). One such
behavioral response to alcohol in C. elegans is the development of acute
tolerance, a component of level of response. As is observed in vertebrate
systems (Crabbe et al., 2013; Erwin et al., 2000; LeBlanc et al., 1975;
Ritzmann & Tabakoff, 1976), including humans (Hiltunena et al., 2000; Kaplan
et al., 1985), the level of response to ethanol in C. elegans involves
development of AFT shortly after ethanol administration (A. Davies et al.,
2004).

To dissect the genetic contribution to ethanol response behavior, which
reflects risk for AUD, researchers have exploited this conserved behavioral
effect in C. elegans. A. Davies et al., (2003b) conducted genetic screens to
identify mutants with reduced sensitivity to ethanol and observed that
exogenously applied ethanol modifies locomotion and egg-laying behavior in
C. elegans. Exposing the worms to short continuous doses of ethanol, they
saw that it produced reversible and dose-dependent decrease in speed of
locomotion and amplitude of body bends during locomotion. Level of response
to alcohol in C. elegans is typically measured by change in locomotion speed
of the worms at different time points after acute exposure to ethanol. There is
an initial depression in locomotion speed that is accompanied by fewer body
bends (initial sensitivity) immediately after exposure. The speed of locomotion
increases over the time course of the assay, despite constant (or in some
instances, increased) internal concentration of ethanol, which supports
previous findings that this increase in speed over time is due to a neuronal
adaptation to the physiological effects of ethanol and not due to decrease in
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the internal ethanol concentration (Davies et al., 2004). This increase in
locomotion speed after the initial depression is termed AFT. It is important to
note that these two components of LR, initial sensitivity and AFT have been
found to be genetically separable (A. Davies et al., 2015).

1.4.

Background research for current project

The Davies-Bettinger lab has identified several genes that modulate neuronal
responses to ethanol in C. elegans including a calcium-activated potassium
channel, Slowpoke protein 1 (slo-1) (A. Davies et al., 2003b), eat-6 which
encodes the alpha-subunit of the Na+/K+ ATPase (Hawkins et al., 2015), a
neuropeptide Y (NPY) receptor-like protein (npr-1) (A. Davies et al., 2004) and
a Ras-family GTPase (rab-3) (Kapfhamer et al., 2008). An area of interest to
the lab is the role of the lipid environment in modulation of ethanol responses.
Using an unbiased genetic screen, they determined that lips-7 and ctbp-1 (Cterminal binding protein 1), a transcriptional regulator of lips-7 affect AFT to
ethanol. In another study looking at the role of ctbp-1 on lifespan in C.
elegans, Chen et al., (2008) observed that ctbp-1 mutants had altered
triacylglycerol (TAG) levels. Since TAGs are components of the lipid
membrane, Bettinger et al., (2012) tested the effect of lipid membrane
environment on AFT by depleting cholesterol, another important component of
the lipid membrane, in the media on which worms are grown. They observed
that worms grown on cholesterol-depleted media displayed suppression of
AFT development, which suggested that the composition and structure of the
lipid membrane is important for normal development of AFT.
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Additional studies in the lab, examining another component of the lipid
environment, have shown that eicasapentanoic acid (EPA), an omega-3 longchain polyunsaturated fatty acid (LC-PUFA), is required for development of
AFT in C. elegans and dietary supplementation of EPA restored WT AFT in
EPA-deficient mutants. Also, supplementation of EPA enhanced AFT
significantly in N2 worms while the basal speeds remained unchanged
implying that LC-PUFAs have an important role in regulating response to
ethanol (Raabe et al., 2014).

In an effort to identify genes involved in the modulation of ethanol responses
in C. elegans, Dr. Joseph Alaimo, a former student in the lab, performed a
microarray analysis of ethanol responsive genes in two strains of C. elegans:
N2 (wildtype, WT) and npr-1(ky13) which is a lf mutation (a C-to-T transition
that introduces a stop codon) that shows significantly higher AFT compared to
N2 (Alaimo, 2013). The npr-1(ky13) strain was chosen due to its marked
increased tolerance to ethanol compared to the WT worms. Comparing the
gene expression profiles between these two strains could potentially reveal
genes that contribute to the increased AFT phenotype seen in npr-1(ky13).
These differentially expressed genes would make excellent candidates for
further research for a role in ethanol responses. Dr. Alaimo compared gene
expression differences between untreated (basal) and acute ethanol treated
N2 (WT) worms and npr-1(ky13) mutant worms and generated three
expression profiles: npr-1(ky13) basal (the set of genes differentially
expressed between the untreated npr-1(ky13) and N2 worms), N2 ethanol
(the set of genes differentially expressed between the ethanol-treated N2
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worms and untreated N2 worms) and npr-1(ky13) ethanol (the set of genes
differentially expressed between the untreated npr-1(ky13) and ethanoltreated npr-1(ky13) worms).

He looked at the intersection of these three expression profiles (i.e., genes
common across the three groups) and found that 20 genes were differentially
expressed in all three profiles, which suggested that these are top candidate
genes in modulating the ethanol response phenotypes (as these are
differentially expressed at the basal level in npr-1(ky13) and also are ethanol
responsive). Out of these 20 genes, based on a ranking system that
considered allele availability, known phenotypes reported on WormBase
(http://www.wormbase.org), neuronal expression and presence of mammalian
homologs, Dr. Alaimo selected acs-2 (acyl-CoA synthase 2) for behavioral
testing and he observed that acs-2(lf) mutants showed significantly reduced
development of AFT compared to N2 (Figure 1A). He then performed an
experiment to determine if the alteration in ethanol response in the acs-2
mutants was due to increased ethanol entry or change in internal ethanol
concentration. He showed that neither of these two phenomena was
responsible for the reduced AFT observed (Figure 1B). This implied that the
difference in behavioral responses to ethanol could be due to physiological
differences in the effects of ethanol in these mutants.
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Figure 1. acs-2 modifies AFT and does not alter ethanol metabolism (A) At 400mM
exogenous ethanol, acs-2(ok2457) display a similar initial sensitivity to N2, but develop
significantly less AFT. acs-2(ok2457);npr-1(ky13) animals also have a similar initial sensitivity
relative to npr-1(ky13) and acs-2(ok2457), but have a reduced AFT that is significantly
different than npr-1(ky13), but not acs-2(ok23457) or N2. (n = 9)(B). Internal ethanol
concentrations are similar across all mutants suggesting the observed behavioral effects are
not due to ethanol metabolism. (n = 4). Error bars are SEM. * P < 0.5 , ** P < 0.01, *** P <
0.001. Reprinted with permission from “Identification and Characterization of Ethanol
Responsive Genes in Acute Ethanol Behaviors in Caenorhabditis elegans”, unpublished
thesis, by J. Alaimo, 2013.
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acs-2 is a gene involved in the first step of mitochondrial beta-oxidation, it
codes for acyl-CoA synthase (ACS) which catalyzes the activation of FA to
fatty acyl CoA (to facilitate entry into the mitochondria) (Van Gilst et al.,
2005a). Lf mutants of acs-2 exhibit accumulation of fat since there is a
disruption of FA activation (Zhang et al., 2011). Dr. Alaimo conducted further
behavioral assays by attempting to knockdown specific genes at different
steps in mitochondrial beta-oxidation (cpt-2, cpt-5, ech-1, ech-2, ech-4, ech-6,
T08B2.7) using RNA interference. These studies revealed that only
knockdown of ech-6 by RNAi altered AFT resulting in enhanced AFT
compared to the control (L4440) (Figure 2), while none of the other RNAi
experiments showed a significantly different ethanol response phenotype from
the control, L4440. This could have been due to inefficient knockdown of
genes by RNAi, so it does not rule out these genes as candidates. Therefore,
these experiments suggested a role for mitochondrial beta-oxidation in
regulating the ethanol response behavior in C. elegans. Treating this as
preliminary evidence, we designed the current project to answer the following
question: Do genes involved in mitochondrial beta-oxidation of FA play a
role in modulating ethanol response in C. elegans?
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Figure 2. Mitochondrial β-oxidation may influence acute ethanol behaviors. (A) At
400mM exogenous ethanol cpt-2(RNAi) and cpt-5(RNAi) animals displayed similar initial
sensitivity and development of AFT relative to control (n = 4). (B) ech-2(RNAi), ech-4(RNAi),
and ech-1(RNAi) mutant animals also display similar initial sensitivity and AFT relative to
control (n = 4). (C) T08B2.7 (RNAi) animals were not different than control for initial sensitivity
or AFT. ech-6(RNAi) mutants displayed an enhanced AFT relative to WT, but initial sensitivity
was not significantly different (n = 8). Error bars represent SEM * P < 0.05, ** P < 0.01, ***P <
0.001. Reprinted with permission from “Identification and Characterization of Ethanol
Responsive Genes in Acute Ethanol Behaviors in Caenorhabditis elegans”, unpublished
thesis, by J. Alaimo, 2013.
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1.5.

Mitochondrial Beta-Oxidation

The first step in understanding the role of mitochondrial beta-oxidation genes
in ethanol response was to characterize and annotate the mitochondrial betaoxidation pathway. FA are a major energy source in multicellular organisms
as they yield large quantities of ATP upon degradation and are also required
for formation of various macromolecules.

FA oxidation is an important

metabolic process that maintains energy homeostasis, particularly under
reduced glucose availability when FA act as the primary source of energy that
can be directly used by most tissues, except the brain. FA are also converted
to ketone bodies which serve as alternate energy sources for all tissues
including the brain (Houten et al., 2010).

Mitochondrial beta-oxidation is the primary pathway of FA degradation and, as
the name implies, it occurs in the mitochondria of eukaryotic cells (Kunau et
al., 1995). Beta-oxidation also occurs in peroxisomes in some higher
eukaryotic organisms, but a major difference between mitochondrial and
peroxisomal beta-oxidation is that peroxisomes typically oxidizes very-longchain FAs (> C22), pristanic acid, and the bile acid intermediates di- and
trihydroxycholestanoic acid, while mitochondria are the site of oxidation for all
other FA species. Also, FAs oxidized in the peroxisomes have to further
undergo complete oxidation in the mitochondria (Wanders & Waterham,
2006). Beta-oxidation in the mitochondria occurs through the following steps
(see Figure 3): (1) Activation: In the cytosol, FA are activated by the addition
of CoA to form acyl CoA, and this is catalyzed by ACS in a two-step process.
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FA reacts with ATP to give fatty acyl adenylate (an intermediate compound)
and inorganic pyrophosphate in the first step, which then react with coenzyme
A (CoA) to form acyl CoA and AMP (2) Transport: Long-chain acyl CoA esters
are transported across the mitochondrial membrane into the matrix for
oxidation by carnitine palmitoyl transferases (CPT) (short and medium chain
acyl CoA esters are activated in the matrix and do not need carnitine shuttle
for transport across the membrane). (3) Dehydrogenation (first): Acyl CoA
dehydrogenases (ACAD/ACDH) catalyze the conversion of acyl CoA to trans2-enoyl CoA. This creation of a trans double bond between C2 and C3
requires FAD+ as electron acceptor that is reduced to FADH2. (4) Hydration:
Trans-2-enoyl CoA is converted to 3-hydroxy acyl CoA by enoyl CoA
hydratase (ECH) enzymes. (5) Dehydrogenation (second): In the second
dehydrogenation, 3-hydroxy acyl CoA is catalyzed by 3-hydroxy acyl CoA
dehydrogenase (HADH/HACD) to form 3-keto acyl CoA, using NAD+ as the
electron acceptor which gets reduced to NADH. (6) Thiolytic cleavage: In the
final step, 3-keto acyl CoA thiolase (KAT) cleaves keto acyl CoA to produce
acetyl CoA and a fatty acyl CoA that is shortened by two carbons which goes
through the same cycle again until it is completely oxidized (Wanders et al.,
2010). Acetyl CoA enters the citric acid cycle to produce carbon dioxide (CO 2)
and water (H2O). The NADH and FADH2 produced in beta-oxidation and citric
acid cycle are utilized in the electron transport chain (ETC). The total energy
yield from each cycle of oxidation is 14 ATP (acetyl CoA enters the citric acid
cycle and yields 10 ATP, NADH and FADH2 enter the ETC and produce 2.5
ATP and 1.5 ATP respectively).
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Figure 3. Mitochondrial beta-oxidation of FA. Reaction steps, enzymes and energy
transfers involved in mitochondrial beta-oxidation of FA. Numbers within boxes at each step
of the pathway correspond to enzymes listed in the top right corner of the figure.

1.5.1. Mitochondrial beta-oxidation in C. elegans
C. elegans is increasingly being utilized to model mammalian metabolic
pathways and associated disorders as a majority of physiological processes
appear to be conserved in these nematodes (Mullaney & Ashrafi, 2010).
Looking specifically at mitochondrial beta-oxidation of FA, the general steps of
the pathway appear to be conserved between mammals and C. elegans
(Table 1). Though conserved in primary function, there is evolutionary
divergence in terms of protein sequence between the mammalian and
C. elegans beta-oxidation enzymes. Other aspects such as substrate
specificity, expression pattern, subcellular localization and auxillary functions
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have not yet been extensively studied in C. elegans to determine the extent of
similarity to their human homologs/orthologs.

Mitochondrial beta-oxidation has not been very well characterized in
C. elegans (Li et al., 2010). There are a significant number of studies
exploring the role of mitochondrial dysfunction in the context of oxidative
stress relating to various metabolic (Lowell & Shulman, 2005) and
neurodegenerative diseases (Ray et al., 2014), lifespan and aging (Dai et al.,
2014). However, only a small number of studies have looked at beta-oxidation
of FA in particular, and these studies focused on subsets of genes mostly with
relevance to transcriptional regulators mediating nutrient response and fat
metabolism (Xu et al., 2015; Van Gilst et al., 2005a; Van Gilst et al., 2005)
and none of these (published to date) have elucidated or comprehensively
reviewed the mechanism of mitochondrial FA beta-oxidation in C. elegans.

A brief overview of each family of genes encoding the enzymes at each step
of beta-oxidation in humans and C. elegans based on published literature is
presented here to give the necessary background to appreciate the wide
range of effects of these genes on ethanol response behavior in C. elegans
which will be discussed in the Results and Discussion section.
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Table 1. Step-by-step comparison of mitochondrial beta-oxidation in humans and C. elegans
Reaction
Enzyme (Human)
Genes (Human)
Enzyme(C. elegans)
Activation:
Acyl CoA
(Long-chain)
Acyl CoA Synthase
Fatty acid
Fatty
Synthetase
ACSL1, ACSL3,
acyl CoA
ACSL4, ACSL5,
ACSL6
(Bubblegum Family)
ACSBG1, ACSBG2
Transport: Fatty
Carnitine palmitoyl
CPT1A, CPT1B,
Carnitine palmitoyl
acyl CoA
Ltransferase
CPT1C
transferase
palmitoyl carnitine
Transport: LCarnitine palmitoyl
CPT2
Carnitine palmitoyl
palmitoyl carnitine
transferase
transferase
acyl CoA
Dehydrogenation
Acyl Co-A
ACADS (short chain)
Acyl Co-A
(first): Acyl CoA
dehydrogenase
ACADSB
dehydrogenase
Trans-2-enoyl CoA
(ACAD)
(short/branched chain) (ACDH)
ACADM (medium
chain)
ACADL (long chain)
ACADVL (very long
chain)

Hydration: Trans-2enoyl CoA
3hydroxy acyl CoA

Dehydrogenation
(Second): 3hydroxy acyl CoA
3-keto acyl CoA

Thiolytic cleavage:
3 keto acyl CoA
Acetyl CoA

Enoyl CoA
hydratase
Hydroxy acyl CoA
dehydrogenase/3ketoacyl CoA
thiolase/enoyl CoA
hydratase
(trifunctional
protein), alpha
subunit
Hydroxy acyl CoA
dehydrogenase
Hydroxy acyl CoA
dehydrogenase/3ketoacyl CoA
thiolase/enoyl CoA
hydratase
(trifunctional
protein), alpha
subunit
Acetyl CoA
transferase
Ketoacyl CoA
thiolase betasubunit of
trifunctional protein

Genes (C. elegans)
acs-1, acs-2, acs-3,
acs-4, acs-5, acs-13,
acs-15, acs-16, acs17, acs-18 (long-chain)
cpt-1
cpt-2
acdh-1 (short-chain),
acdh-3
(short/branched
chain), acdh-4
(short/branched
chain), acdh-7
(medium chain), acdh8 (medium chain),
acdh-10 (medium
chain), acdh-12 (very
long chain)
ech-6 (short chain)

ECHS1 (short chain)

Enoyl-CoA hydratases

HADHA

Enoyl-CoA
hydratases/long-chain
3-hydroxyacyl-CoA
dehydrogenase

ech-1.1, ech-1.2

HADH

Hydroxy acyl CoA
dehydrogenase
Enoyl-CoA
hydratases/long-chain
3-hydroxyacyl-CoA
dehydrogenase

F54C8.1, hacd-1,
B0272.3
ech-1.1, ech-1.2

ACAA2

Acetyl CoA transferase

acaa-2

HADHB

Ketoacyl CoA thiolase
beta-subunit of
trifunctional protein

B0303.3

3-keto acyl CoA
thiolase

kat-1

HADHA
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1.5.1.1.

Acyl CoA Synth(et)ases (ACS)

In humans, approximately 26 ACS enzymes have been identified and
characterized or predicted to date (Watkins et al., 2007). These enzymes
catalyze thioesterification of FA into fatty acyl CoA which can either enter the
beta-oxidation pathway or other pathways that form membrane phospholipids,
cholesterol esters and activation of certain transcriptional and signaling
pathways as shown in Figure 4 (Cooper et al., 2015).

Figure 4. Metabolic reactions of acyl-CoAs. Long-chain FAs are synthesized de novo from
acetate or enter cells from the plasma. They are converted to acyl-CoAs by ACSL and
ACSVL. The reaction is reversed by acyl-CoA thioesterases (ACOT). Acyl-CoAs can be
elongated and desaturated, converted to acylcarnitines, and metabolized to CO2 via
mitochondrial and peroxisomal enzymes, esterified to glycerol-3-phosphate to form
lysophosphatidic acid (LPA), phosphatidic acid (PA), and TAG, and esterified to
monoacylglycerol (MAG) to form diacylglycerol (DAG). Both phosphatidic acid and
diacylglycerol are precursors for all the glycerophospholipids. Acyl-CoAs are also esterified to
retinol and cholesterol, acylated to proteins, and incorporated into ceramide to form
sphingolipids. Lipolysis of these products releases FA back into cellular pools. Triacylglycerol,
cholesterol esters, and retinol esters are stored in lipid droplets within cells or secreted from
specialized cells as lipoproteins or milk constituents. NEFA, non-esterified fatty acid. Reused
with permission from “Physiological Consequences of Compartmentalized Acyl-CoA
Metabolism”, by Cooper et al., 2015, Copyright 2015, by the American Society for
Biochemistry and Molecular Biology, Inc.
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ACS enzymes have been broadly categorized into distinct groups based on
their substrate-specificity, which is mostly defined by chain length of the FA
substrate. There has been significant evidence from mice and cell line studies
to show that members of the ACS family exhibit preference for specific chain
lengths of FA. For example, Li et al. (2009) performed liver-specific knockout
experiments in mice to show that ACSL1 is important for oxidation of long
chain FA in the mitochondria. Another study (Marszalek et al., 2005) found
that ACSL3, ACSL4 and ACSL6 preferentially activate PUFA for oxidation.

The C. elegans genome encodes at least 22 ACSs (WormBase) but there
have been very few studies characterizing these enzymes and their roles in
fat metabolism. One study looking at acs-3, which is predicted to encode a
long chain ACS, showed that it has a role in regulating fat storage (Mullaney &
Ashrafi, 2010) and acs-4 and acs-5 were shown to be involved in the
serotonergic regulation of fat storage in C. elegans (Srinivasan et al., 2008).
For most of these genes, there has been no recorded lf phenotype, and their
functions (including their roles in beta-oxidation) and substrate-specificity
have been predicted solely based on their orthology/homology to human or
mouse ACS genes.

1.5.1.2.

Carnitine Palmitoyl Transferases (CPT)

Carnitine palmitoyl transferases (CPTI and CPTII) transport long chain fatty
acyl CoAs across the mitochondrial matrix for oxidation. CPTI is located on
the outer mitochondrial membrane and, since it catalyzes the rate-limiting step
of FA oxidation (transport of fatty acyl carnitine), it is regulated tightly by
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malonyl CoA, which is the first intermediate product in FA synthesis. This
allows for a physiological balance between FA synthesis and degradation.
CPTII is located on the inner mitochondrial membrane as a membraneassociated enzyme that facilitates reconversion of long-chain fatty acyl
carnitine into fatty acyl CoA once it enters the matrix. In humans, CPTI (gene:
CPT1) and CPTII (gene: CPT2) have been studied extensively both with
respect to structural and functional characterization (Woldegiorgis et al., 2000;
Yamzaki, 2004) and their roles (particularly CPT1) in various neurological
(Virmani et al., 2015; Xie et al., 2016) and metabolic diseases (Flanagan et
al., 2010; Schreurs et al., 2010).

There are 6 members in the CPT family encoded in the C. elegans genome
(WormBase), of which cpt-1 and cpt-2 are orthologous to the human CPT1A
and CPT2 genes respectively, while the other CPT genes (cpt-3,4,5,6) are
predicted to also have acyl CoA transferase function. The literature available
on this family of genes is mostly in the area of fat, adiposity and lipid
metabolism regulation (Brock et al., 2007) by specific transcription factors
such as nhr-49 (Van Gilst et al., 2005b) and mdt-15 (Taubert et al., 2006)
through altering expression levels of these CPT genes.

1.5.1.3.

Acyl CoA dehydrogenases (ACAD/ACDH)

ACAD/ACDH, as the name implies, catalyze the dehydrogenation of fatty acyl
CoA once it enters the mitochondria. These are flavoprotein enzymes that
require flavin adenine dinucleotide (FAD) as a co-factor to catalyze reactions.
Nine major ACADs have been identified in eukaryotes, with five of these
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involved in beta-oxidation of FA (SCAD, MCAD, LCAD, vLCAD, vLCAD2),
and the other four involved in the catalysis of branched-chain amino acid
synthesis (i2vD, i3vD, GD, iBD) (Ghisla & Thorpe, 2004). Based on their
substrate specificity, the ACADs participating in beta-oxidation can be
categorized into four groups but there is a certain degree of overlap in their
substrate chain-lengths: (1) short-chain ACAD (SCAD) that preferentially act
on C4-C6 fatty acyl-CoAs (2) medium-chain ACAD (MCAD) which catalyzes
dehydrogenation of C6-C10 fatty acyl-CoAs (3) long-chain ACAD (LCAD)
which acts on C10-C14 fatty acyl-CoAs and (4) very long-chain ACADs
(vLCAD, vLCAD2) that is specific to C14-C20 fatty acyl-CoAs (Leslie et al.,
2014). Since deficiencies of these enzymes in humans lead to serious
metabolic consequences that can be detected in newborn screening, they
have been well-studied and numerous groups have performed protein
crystallization, functional analyses and gene knockout studies in animal and
cell models.

However, in C. elegans, which has 13 ACDH genes (WormBase), a detailed
crystal structure analysis has been performed only on acdh-11. Li et al.,
(2010) reported that while acdh-11 shares 26% protein sequence identity with
the human vLCAD, it is quite different from its human homolog in terms of
structural properties. It shows affinity for C11/C12-FA but does not appear to
have dehydrogenase activity, which suggested that acdh-11 could be involved
in sequestering long chain FA (specifically C11/C12), and thus may play a
role in regulation of FA desaturation (Ma et al., 2015). This differential in
function of acdh-11 and its lack of dehydrogenase activity could explain the
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low percentage of protein sequence similarity it shares with the human
VLCAD. The other ACDH enzymes in C. elegans that have been found to be
orthologous to the five different human ACADs are: acdh-1, acdh-2 (shortchain), acdh-3, acdh-4 (short/branched chain), acdh-7, acdh-8, acdh-10
(medium chain), acdh-5, acdh-6 (long chain) and acdh-12 (very long chain).
acdh-13, although predicted to possess ACDH activity, does not have a clear
human ortholog.

1.5.1.4.

Enoyl CoA hydratase (ECH), 3-hydroxy acyl CoA dehydrogenase

(HACD/HADH) and 3-keto acyl CoA thiolase (KAT):
These three classes of enzymes together catalyze the final steps of
mitochondrial beta-oxidation. ECH catalyzes the addition of one H2O molecule
to trans-2-enoyl CoA to form 3-hydroxy acyl CoA thioester (Agnihotri & Liu,
2003), which is subsequently acted upon by HACD/HADH to form 3-keto acyl
CoA, it is then cleaved by KAT, resulting in acetyl CoA and an acyl CoA
molecule that is shortened by two carbons.

Like the ACADs, these enzymes also exhibit substrate-specificity based on
chain length of acyl CoA. The long chain fatty acyls CoAs are metabolized by
long-chain 2,3-ECH (LYHD), long-chain hydroxy acyl coA dehydrogenase
(LCHAD) and long-chain KAT (LKAT). As the chain length of the substrate
shortens,

short-chain

2,3-ECH

(SHYD),

a

medium/short-chain

L-3-

hydroxyacyl-CoA dehydrogenase (M/SCHAD), and medium-chain, short-chain
KAT (MKAT, SKAT) are activated to complete the oxidation (Bennett et al.,
1996; Wanders et al., 1999).

24

In higher eukaryotes, the three enzymes catalyzing the final steps of
mitochondrial beta-oxidation for long-chain fatty acyl CoA (LHYD, LCHAD and
LKAT) exist as one trifunctional membrane-bound protein complex called the
Mitochondrial Trifunctional Protein (MTP). This protein complex contains four
alpha and four beta subunits; the alpha subunits are responsible for the
ECH/HADH activity while the beta subunits carry out the thiolytic cleavage
(Rakheja et al., 2002). The alpha subunit is encoded by the HADHA gene and
the beta subunit is catalyzed by the HADHB gene. Mutations in these two
genes cause LCHAD and MTP deficiencies in humans, the former being more
common (Ushikubo et al., 1996).

C. elegans genes encoding the enzymes catalyzing these last three steps
include the ECH family, hacd-1 and kat-1. The ECH family in C. elegans has
10 members, and among these ech-1.1 and ech-1.2 are orthologs of the
human MTP and have ECH/long-chain HADH activity. ech-6 and ech-7 are
orthologous to the human short-chain ECH, ECSH1. ech-8 and ech-9 are
predicted to function in the peroxisomes due to their similarity to the human
bifunctional protein EHHADH which exhibits ECH and HADH enzyme activity
and is involved in peroxisomal oxidation of FA. ech-4, containing an acyl CoA
binding domain and ECH domain, has been shown to affect the beta-oxidation
of unsaturated FA (Elle et al., 2011). There is not enough information on ech3 and ech-5 to determine if they have a role in beta-oxidation.

1.6.

Goal of Present Study
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My goal in this project was to characterize the role of mitochondrial betaoxidation in the behavioral response to ethanol using C. elegans. Using the
results of Dr. Alaimo’s microarray data (of ethanol responsive genes), and his
observations of the effects of loss of function of acs-2 and ech-6 genes of
mitochondrial beta-oxidation on ethanol response behaviors as preliminary
data, we asked how mitochondrial beta-oxidation either through its substrates,
products, intermediate compounds or enzymes plays a role in mediating
ethanol responses in C. elegans. For this purpose, we selected candidate
genes that catalyze each step of the pathway based on specific criteria and
performed behavioral assays on the lf mutants of these genes to determine
their ethanol response phenotype. We hypothesized that some of these
mutants would exhibit altered ethanol response phenotypes compared to the
WT, which would indicate that those genes have a role in the behavioral
responses to ethanol.

1.7.

Specific Aims

1. Selection of candidate genes in the mitochondrial beta-oxidation
pathway for testing in ethanol response assays.
2. Behavioral testing of backcrossed lf mutant strains and RNAi-fed
worms using locomotion assays, to determine the roles of candidate
genes in altering ethanol response phenotypes
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2. MATERIALS AND METHODS

2.1 Selection of candidate genes
The first aim of the project was to select candidate genes of interest in the
mitochondrial beta-oxidation pathway, which could be tested for a role in
ethanol response behavior. I performed a review of literature on mitochondrial
beta-oxidation of FA and found that there were several versions of the
mitochondrial beta-oxidation pathway (in humans and C. elegans) in various
published articles. Though the steps of the pathway were consistent across
publications, there was significant variation in the enzymes and genes
catalyzing each step. Therefore, to obtain an exhaustive list of genes involved
in this pathway, I decided to use the mitochondrial beta-oxidation pathways of
human

(http://www.genome.jp/kegg-bin/show_pathway?hsa00071)

and

C. elegans (http://www.kegg.jp/kegg-bin/show_pathway?cel00071) illustrated
on the KEGG Pathway database, as these were the most comprehensive
annotated versions available. We then formulated specific exclusion criteria
based on which genes would be eliminated from this list. All genes that could
not be eliminated based on the exclusion criteria were included in the list of
candidate genes to be tested for their roles in responses to ethanol. The
exclusion criteria were: strong (literature) evidence showing that the gene
does not play a role in mitochondrial beta-oxidation, genes that were shown to
have a role in biological processes unrelated to mitochondrial beta-oxidation
and genes that were orthologous to human genes that were not involved in
mitochondrial beta-oxidation of FA. For example, acs-8 aka mec-18, is one of
the genes in the ACS family. It is expressed only in touch cells and is involved
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in sensory mechanotransduction and therefore is highly unlikely to play a role
in beta-oxidation of FA.

For the second aim, prior to testing for ethanol response behaviors, I
backcrossed the 23 lf mutants obtained from the Caenorhabditis Genetics
Center (CGC) at least twice (2x) to N2 (WT) worms. Two of the 23 mutants,
kat-1 and ech-7 were already backcrossed 6x and 10x respectively. So kat-1
was not backcrossed further. However, the ech-7 lf mutant carried a deletion
in another gene, paqr-2, so this strain was backcrossed to N2 once more.
Prior to testing, I ensured that the paqr-2 variant allele was removed from the
background using PCR with primers for the paqr-2 allele to genotype the F1
and F2 offspring obtained from the backcross, and maintained the F2s that
had the mutant ech-7 allele and the WT paqr-2 allele.

2.2 Maintaining strains
Worms were maintained on petri plates containing nematode growth media
(NGM). After seeding the plates with OP50, which is a strain of E. coli used in
the laboratory as food source for C. elegans (refer ‘seeding plates with
OP50’), five adult hermaphrodites (of N2, the WT strain used in lab) were
plated on to seeded plates and stored at 20°C. For the mutant strains, six to
eight adult hermaphrodites were maintained at 20°C. VC2240: Since the
homozygous mutant of this strain is sterile, it is balanced by a GFP-carrying
balancer,

hT2

[bli-4(e937) let-?(q782) qIs48]

(I;III).

For this strain,

heterozygote adults with GFP were picked for maintaining the strain.
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2.3 Chunking
This was done to maintain the mutant strains obtained from the CGC and also
to salvage worms from starved plates. A small chunk of NGM agar (from the
CGC/starved plates) was cut out using a spatula that was first sterilized using
70% ethanol and flamed, and the chunk was placed on the edge of the OP50
lawn on a seeded plate. The chunked plate was left on the bench for a few
hours; this allows worms from the chunk to crawl onto the OP50 lawn. These
worms are then transferred to another seeded plate and maintained.

2.4 Making OP50
OP50 is the strain of E. coli that worms are fed when being maintained in lab.
A single colony of OP50 was picked using an inoculation loop from the OP50
stock culture plate and stirred into 50 mL of autoclaved LB. This was then
allowed to grow overnight (~16 hours) at 37°C, with the lid of the container
screwed on loosely, to allow for aeration. After ~16-20 hours the culture was
removed from 37°C and shaken or swirled to check if the LB has turned
cloudy, which indicates bacterial growth. It was then stored at 4°C for future
use. OP50 was typically used within 30-45 days after preparation.

2.5 Seeding plates with OP50
Approximately two drops of OP50 were pipetted onto the NGM plates and
spread into a square lawn on the center of the plates and allowed to typically
grow overnight at room temperature before using the plates for maintaining
worms.
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2.6 C. elegans strains
Table 2. List of C. elegans strains used for the project. The genotype (Gene, allele,
chromosome) is depicted for each strain and the gene of interest is highlighted. The strains
generated by EMS mutagenesis for the Million Mutations Project (MMP) carry numerous
mutations and are indicated by the acronym MMP next to the strain name. For these strains,
only the genotype of interest is given.
Strain Name
Genotype
Effect on protein
N2 (var. Bristol)
WT
NA
VC40812 (MMP)
acs-3(gk826522)V
Y324Ochre
VC2240
acs-4(ok2872)III/hT2 [bli-4(e937) letInsertion/deletion (affects
?(q782) qIs48] (I;III)
coding exon and intron)
RB2015
Y76A2B.3(ok2668)III
Deletion (not curated)
RB2147
acs-13(ok2861)I
Deletion (affects coding exon
and intron)
RB1377
acs-17(ok1562)X
Deletion (not curated)
VC20634 (MMP)
acs-22(gk364606)V
R597Opal
R470Opal
R600Opal
VC20616 (MMP)
cpt-3(gk356297)III
Q636Amber
VC40798 (MMP)
cpt-4(gk818803)V
S519Opal
VC40360 (MMP)
cpt-6(gk594576)V
W39Opal
VC1087
acdh-1(ok1514)I
Deletion (not curated)
VC20502 (MMP)
acdh-2(gk143151)II
W19Opal
G125E
W185Opal
VC40973 (MMP)
acdh-5(gk907299)I
Q146Amber
VC40929 (MMP)
acdh-6(gk886629)III
W51Opal
VC40288 (MMP)
acdh-7(gk556025)X
Q361Ochre
VC40665 (MMP)
acdh-11(gk753061)III
L119Amber
L110Amber
VC41029 (MMP)
F54D5.7(gk936057)II
W169Opal
VC40235 (MMP)
ech-1.2(gk527451)I
Q142Ochre
Q142Ochre
Q116Ochre
QC119
ech-7(et6)I; paqr-2(tm3410)III
V175M
RB2101
R09B5.6(ok2776)V
Deletion (affects coding exon
and intron)
RB1606
ife-1&F53A2.7(ok1978)III
Insertion (affects coding exon
and intron)
VC2462
T02G5.4(ok3160)II
Insertion (not curated)
RB2566
T02G5.7(ok3574)II
Deletion (not curated)
VS24
kat-1(tm1037)II
Insertion (affects coding exon
and intron)

2.7 DNA Isolation
DNA isolation was performed in order to obtain genomic DNA that was used
as the template for PCR.
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2.7.1 DNA Isolation for PCR
A full plate of worms (obtained by plating five adult hermaphrodites on a
seeded plate and letting them grow and produce a population for three days)
was used for DNA isolation. These worms were washed off the plate using
~1.7 mL ddH2O into a 1.5 mL Eppendorf tube and centrifuged at 21,000 rcf
(high speed) for 30 seconds. Most of the supernatant was removed, and one
mL ddH2O was added and centrifuged again for one min. The supernatant
was removed until 0.1 mL of solution remained in the tube. The pellet was
disturbed by shaking and the tube was placed at -80°C for 15 minutes to lyse
the cells. Thirty three microlitres of a master mix made of lysis buffer and 10
mg/mL Proteinase K (35 μL lysis buffer + [(12/1000) x 35] μL Proteinase K)
was added to the tube. The tube was incubated at 60°C for 90 minutes to
digest the proteins, followed by a 20 minute incubation at 95°C to inactivate
the Proteinase K. This lysate containing DNA was stored at -20°C (detailed
protocol and recipes for solutions used are in Appendix I).

2.7.2 DNA Isolation for Single Worm PCR (SWPCR)
A master mix of 95 μL lysis buffer and five microlitres of 10 mg/mL Proteinase
K was prepared and three microlitres of this solution was added to a 0.2 mL
PCR tube. A single worm (on which PCR is to be performed) was placed in
the solution and the tube was placed at -80°C for 20 minutes, followed by a
60 minutes incubation at 60°C and 15 minutes at 90°C. The DNA prepared
was stored at -20°C (detailed protocol in Appendix I).

31

2.8 Polymerase Chain Reaction (PCR)
PCR was performed on all the mutant strains received from the CGC to
confirm presence of mutant allele in the strains and for genotyping the F1 and
F2 generations of backcrossed mutant strains.

2.8.1 Primers for PCR
Primer sequences were obtained from the website (https://cgc.umn.edu) for
some mutant strains (Appendix II, Table 14), and for strains that did not have
this information on the CGC or WormBase, I designed primers using the NCBI
Primer-BLAST tool (www.ncbi.nlm.nih.gov/tools/primer-blast) using the DNA
sequence of mutant strains obtained from WormBase (Appendix II, Table 15).
The DNA sequence in the mutated region (that is either deleted or carries a
complex substitution in the mutant strain) along with the flanking sequences
(a few hundred base pairs on either side) was used to generate primers and
the best primer pair was chosen based on primer length (optimal length of
PCR primers is 18-22 base pairs, which is long enough for adequate
specificity and short enough for primers to bind easily to the template at the
annealing temperature), optimum melting temperature (temperature at which
one half of the DNA duplex will dissociate to become single stranded and
indicates the duplex stability. Primers with melting temperatures in the range
of 52-58°C produce the best results) and self-complementarity (predictive of
the tendency of primers to anneal to each other, which hinders amplification of
template DNA).

2.8.2 PCR Setup
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Unless mentioned otherwise, all polymerase chain reactions (PCR) were set
up according to the following specifications (see Appendix I for detailed
protocol):
Table 3. PCR Reaction components
Component

Volume per sample (μL)

Final concentration

ddH2O

6.7

--

10X DreamTaq Green Buffer

1.0

1X

DreamTaq DNA polymerase

0.1

0.5 U

dNTP (10mM)

0.2

2 mM

Forward Primer (10μM)

0.5

5 μM

Reverse Primer (10μM)

0.5

5 μM

DNA

1.0

--

(5U/μL)

Table 4. Standard PCR conditions
Condition

Temperature

Time

Initial Denaturation

94°C

2 minutes

Denaturation

94°C

15 seconds

Annealing

45-69°C*

45 seconds

Extension

72°C

1 minute/kb*

Final Extension

72°C

5 minutes

35 cycles

*Annealing temperature and extension time vary depending on melting temperature of
primers (Tm) and product size respectively.

2.8.3 Temperature gradient PCR
A trial PCR was set up for each of the primer pairs at 5-6 different annealing
temperatures within a specific range that were picked based on the melting
temperature of each primer pair using one microlitre of N2 DNA as template,
to determine the optimal annealing temperature for each primer pair. The
PCR reaction mix and the PCR program were set up as mentioned in section
2.8.2. Based on the band intensity (indicates robust amplification) and minimal
non-specific bands (due to smaller non-specific amplification or primer-
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dimers) when the PCR product is run on an Agarose gel, the best temperature
was determined and used as annealing temperature for that primer pair for
further PCR reactions.

2.8.4 Single worm PCR (SWPCR)
SWPCR was mainly performed to determine genotypes of progeny from
crosses (see Appendix I for detailed protocol).
Table 5. PCR reaction components for SWPCR
Component

Volume per sample (μL)

Final concentration

ddH2O

13.4

--

10X DreamTaq Green Buffer

2.0

1X

DreamTaq DNA polymerase

0.2

0.5 U

dNTP (10mM)

0.4

2 mM

Forward Primer (10μM)

1.0

5 μM

Reverse Primer (10μM)

1.0

5 μM

DNA

3.0

--

The three microliters DNA isolated from a single worm (refer to section 2.7.2)
is used as template DNA to which 18 μL of the master mix is added. The PCR
program is set up as detailed in 2.8.2.

2.9 Restriction digestion
For mutants that contain a single nucleotide polymorphism (SNP) within a
restriction site, PCR was followed by restriction digestion to determine
genotype of the SNP, using the appropriate restriction enzyme. The restriction
digestion mix was set up as shown in Table 6, for a final volume of 10 μL.
This type of genotyping using restriction digestion to detect Single Nucleotide
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Polymorphisms (SNP) is called snipSNP. Restriction enzymes recognize and
cleave (or ‘snip’) specific sequences of nucleotides. I chose particular
enzymes that cut at nucleotide sequences, which contain the WT or variant
allele at the target SNP, so that digestion using this enzyme resulted in
cleaving of the amplicon at the SNP, in either the WT allele carriers or mutant
allele carriers. Detection of genotype was based on the number of fragments
and size of fragments observed when the digested PCR products were run on
an Agarose gel. The list of restriction enzymes and digest conditions used are
given in Table 16, Appendix II.
Table 6. Restriction digestion reaction mix components
Component

Volume per sample (μL)

ddH2O

3.5

Buffer*

1.0

Restriction enzyme

0.5

PCR product

5.0

*Manufacturer guidelines were followed for buffer volume in case of buffer
concentrations other than 10X and for setting up the digest conditions
(temperature and time).

2.10

Agarose Gel Electrophoresis

We used Agarose gel electrophoresis for the following: to determine product
sizes of amplified DNA fragments in WT and mutant worms to determine
genotype based on the difference in product size (in case of mutants carrying
deletions, the size of the amplified product in mutant worms would be smaller
compared to that of WT worms); to determine the fragment size of restriction
digested PCR products; for detecting genotype in snipSNP by running the
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restriction digested fragments on a gel; to estimate the concentration of DNA
in PCR samples sent for sequencing. The Agarose gels used for this project
were 1% (if the predicted product size was greater than 600 bp), 1.5% (300600 bp, if the predicted product sizes differed by at least 100 bp) and 2% (50300 bp, if the predicted product sizes differed by at least 50bp). An Agarose
gel was prepared using a specific amount of Agarose (depending on the
percentage and size of the gel, for example, to prepare a 1% large gel of 100
mL, 1g of Agarose was used). The Agarose was dissolved in a specific
volume of 0.5X TBE (Tris/Borate/EDTA) buffer and the solution was heated
until the Agarose dissolved completely in the buffer. Three microliters
Ethidium Bromide, a DNA-intercalating agent, was added to this and the gel
was poured into a gel tray that has combs (to form lanes). This setup was
allowed to cool down, the combs were removed and the gel was placed in a
gel tank containing 0.5X TBE buffer. Five microlitres of sample (PCR
product/digested sample) was loaded into each lane and an appropriate DNA
ladder was used to serve as a guideline to determine the size of sample
bands. The gel was run at a set voltage (80V-100V) for 45-120 minutes
(depending on size of fragments) and then visualized in the UV
transilluminator to determine band sizes of samples and estimate DNA
concentration.

2.11

DNA sequencing

Sanger sequencing was performed for SNPs that were not detectable by
restriction digestion or PCR. Sequencing was also used to confirm the results
obtained by restriction digestion or PCR, in case of ambiguous results or
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failed digests. PCR was performed using primers flanking the SNP to
generate a reaction volume of 10 μL (in case of SWPCR, 21 μL). The
concentration of DNA was estimated from running the samples on an Agarose
gel and comparing the band intensity to a DNA ladder (of known band sizes
and DNA concentrations). Two microlitres of ExoSAPTM (a PCR product
cleanup reagent) was added to five microliters of PCR product and incubated
at 37°C for 15 minutes, to degrade excess primers and dNTPs, followed by 15
minutes incubation at 80°C to inactivate the ExoSAP reagent. The
sequencing reaction was prepared according to the standard guidelines (for
Sanger sequencing using Purified Template) provided by GENEWIZ
(Appendix I). The purified PCR product was diluted for a final volume of 10 μL
and an appropriate final concentration (ng/μl) based on the size of the PCR
product (see Table 12 in Appendix I). Five microlitres of diluted forward primer
(1 in 20 dilution: 95 μL ddH2O and five microliters 100μM primer) was added
to the diluted, purified PCR product to make up a 15 μL sequencing reaction.
All sequencing reactions thus prepared were sent to the GENEWIZ facility for
Sanger sequencing. 4Peaks software was used to interpret SNP genotype by
visualizing the sequence trace files received from GENEWIZ.

2.12

RNA interference (RNAi)

All the RNAi experiments were performed based on the protocol published by
(Kamath et al., 2003). I planned to perform RNAi for 14 candidate genes that
did not have lf mutants available from CGC. Bacterial clones containing the
sequences coding for double stranded RNA complementary to the genes of
interest were obtained from the RNAi library generated by Ahringer. The RNAi
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bacterial strain was not available in the library for one of the genes (cpt-1). For
the other 13 genes, the corresponding bacterial colony was scraped using a
micropipette tip and suspended in 2 mL of LB containing 50 μg/mL Ampicillin.
This was also done for dpy-17, which we used as a positive control used for
RNAi and L4440, which is the empty bacterial vector (used as ‘WT’ control for
behavioral assays). These cultures were allowed to grow for 16 hours by
incubating in the shaker at 37°C and 250 rpm (Appendix I: Making RNAi
cultures from frozen stock). Five of the 13 RNAi cultures did not show any
growth (acs-15, acs-18, acdh-3, F54C8.1, B0272.2) and hence the process
was repeated for these, with no success. One and half milliliters of the other
grown cultures were used for freezing by adding 300 μL of glycerol, in cryotube vials (Appendix I: Freezing RNAi Cultures). The grown bacterial cultures
were also streaked on LB plates containing Ampicillin (50 mg/mL) and
Tetracycline (15 mg/mL) using an inoculation loop, and incubated at 37°C for
16 hours (Appendix I: Preparing ampicillin + tetracycline plates for RNAi).
These plates were then stored at 4°C and used for preparing liquid cultures of
RNAi. Single colonies were picked from the plates and suspended in five
milliliters of LB containing 50 μg/mL Ampicillin and grown for 16 hours in the
shaker at 37°C and 250 rpm to obtain cultures that were ready to be used for
feeding worms. Prior to performing behavioral assays, the bacterial clones in
each of these cultures were confirmed by Sanger sequencing. For this, three
milliliters of the culture was used for DNA extraction, which was performed
using the Invitrogen PureLink HQ Mini Plasmid Purification Kit (Appendix I:
Plasmid DNA extraction using Invitrogen PureLink HQ Mini Plasmid
Purification Kit) and the plasmid DNA was quantified using a NanoDrop
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machine (DNA concentrations are attached in Appendix II, Table 17). The
samples were prepared for sequencing according to the requirements given
on GENEWIZ for Purified Templates (Appendix I: Sanger sequencing sample
preparation using Plasmid DNA template). DNA was diluted to a final
concentration of 50 ng/μL in 10 μL and five microliters of diluted (1 in 20
dilution) UC19 primer was added to each diluted sample. Sanger sequencing
was done by GENEWIZ and the sequences obtained were input in NCBI
BLAST to confirm the gene sequence. All samples had the correct sequence
except acs-16, for which sequencing was not successful due to lack of
priming (this was repeated once, but with the same outcome). Therefore,
RNAi bacterial cultures were successfully grown and confirmed for seven
genes (W03F9.4, acdh-4, acdh-8, acdh-10, acdh-12, ech-1.1, B0303.3) for
which behavioral assays on ethanol were performed.
For the confirmed gene sequences, 800 μL of each RNAi culture was seeded
on NGM plates containing Carbenicillin (50 mg/mL) and IPTG (0.1 M)
(Appendix I: Carbenicillin Plates for RNAi). N2 worms in the L4 stage were
placed on each of these RNAi plates approximately 24 hours before the
behavioral assay on ethanol was to be performed. The dpy-17 RNAi was used
as a positive control to confirm that RNAi setup was functional (the worms fed
with dpy-17 RNAi culture exhibited ‘dumpy’ phenotype, and at least threefourths of the worms on this plate need to be ‘dumpy’ for the RNAi to be
considered successful). This was done each time new RNAi cultures were
made or new RNAi plates were prepared. The behavioral assays on ethanol
were performed as described in section 2.14, using L4440 (N2 worms fed with
E. coli carrying empty vector) as the WT strain.
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2.13

Backcrossing mutant strains

All of the lf mutant strains received from the CGC that were not already
backcrossed to N2 at least twice, were backcrossed twice to N2 (2x cross) to
decrease the number of other mutations in the strain that could affect the
behavioral response to ethanol. These 2x backcrossed mutants were used for
behavioral assays on ethanol. The ones that showed a significantly different
ethanol response phenotype compared to N2 were further backcrossed four
additional times to N2 for a final number of 6x backcrosses. 6x generally will
generate a mostly WT genetic background (~98.375%) and is the generally
accepted standard in C. elegans genetics (Boulin & Hobert, 2012; Zuryn et al.,
2010).

Refer to figures 5 and 6 for a graphic step-wise representation of the
backcross with the genotypes and their ratios at each generation. Figure 5
represents the backcross for genes on autosomes (chromosomes I-V) and
figure 6 represents the backcross for genes on the X-chromosome.

I set up Cross I using mutant hermaphrodites in the L4 stage with N2 males
(in 5:10 ratio) and this is considered as ‘day 1’ of the cross. On the following
day (day 2), each of the mated mutant hermaphrodite adults were transferred
to separate freshly seeded plates and allowed to lay eggs. Three days later
(day 5), five F1 hermaphrodite progeny (which are all heterozygous) were
transferred to a separate seeded plate from each one of the day 2 plates.
These plates are stored for backup if the second cross fails and needs to be
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repeated. Also, on day 5, F1 males from these day 2 plates were used to set
up a mating with N2 hermaphrodite L4s (in a ratio of 10:5) for Cross II. The
next day (day 6), each one of the mated N2 hermaphrodite adults from Cross
II were picked to individual plates and allowed to lay embryos. Four days later
(day 10), ten or twelve F1 adult hermaphrodites from these plates were picked
to individual plates and allowed to self-fertilize and lay eggs overnight.
SWPCR was performed on these F1 hermaphrodites from cross II, on the
following day (day 11), to determine the genotype. 8-10 F2 hermaphrodites
(from the heterozygous F1 plate) were picked to individual plates four days
after PCR, and this was repeated on the next day (day 16) and these are
allowed to lay eggs overnight. SWPCR was performed on these F2 progeny
to select the homozygous mutant worms. The embryos from the homozygous
mutant F2 were used to maintain a population of 2x backcrossed mutant
worms.

One of the mutant strains (VC2240, acs-4(ok2872)) was balanced by bli-4and

GFP-marked

translocation

(acs-4(ok2872)

III/hT2 [bli-4(e937)

let-

?(q782) qIs48] (I;III)), since this is a homozygous sterile deletion. Therefore,
for backcrossing this strain to WT background, it was first outcrossed to the
balancer strain (hT2 [bli-4(e937) let-?(q782) qIs48] (I;III), obtained from Dr.
Laura Mathies), followed by cross to N2. The steps in this cross are shown in
Figure 7.
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2x backcross for mutants of genes on Chr I-V

d1

Mutant hermaphrodite L4

X

N2 Adult Male (Cross I)

mut

+

mut

+

d2

Singled mated mutant hermaphrodite adult

d5

F1 progeny (50% hermaphrodites; 50% males)
mut
+
F1 male

d6
d10

X

N2 hermaphrodite L4

mut

+

+

+

(Cross II)

Singled mated N2 hermaphrodite adults
F1 progeny of Cross II (50% hermaphrodites; 50% males)
mut

+

+

+

(1:1 ratio)

Singled F1 hermaphrodite adults (allowed to self-fertilize and lay embryos)
d11

SWPCR of F1 hermaphrodite adults that were allowed to lay eggs

d15

F2 progeny from heterozygous F1 hermaphrodite adults
+
+

mut
+

mut
mut

(1:2:1 ratio)

Singled 8-10 F2 hermaphrodite adults from the heterozygous mutant
hermaphrodite adults from SWPCR of d11 (allowed to self-fertilize and lay
embryos)
d16

SWPCR of singled F2 hermaphrodite adults from d15
Again singled 8-10 F2 hermaphrodite adults from the homozygous mutant
hermaphrodite adults from SWPCR of d11 (allowed to self-fertilize and lay
embryos)

d17

SWPCR of singled F2 hermaphrodite adults from d16
Selected worms from the homozygous mutant F2 hermaphrodite adult plates to
maintain 2x backcrossed mutant strain

Figure 5. Genotypes and ratios of outcrossed progeny in the 2x outcross of mutants of genes on the
autosomes (Chromosomes I-V)
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2x backcross for mutants of genes on X-Chromosome
d1

Mutant hermaphrodite L4

X

N2 Adult Male (Cross I)

mut

+

mut

o

d2

Singled mated mutant hermaphrodite adults

d5

F1 progeny (50% hermaphrodites; 50% males)
mut
+
F1 male

X

N2 hermaphrodite L4

(Cross II)

+
+
d6
d10

Singled mated N2 hermaphrodite adults
F1 progeny of Cross II (50% hermaphrodites; 50% males in 1:1 ratio)
mut

+
Singled F1 hermaphrodite adults (allowed to self-fertilize and lay embryos)
d15

F2 progeny from F1 hermaphrodite adults

+

mut

mut

+

+

mut

(1:2:1 ratio)

Singled 8-10 F2 hermaphrodite adults (allowed to self-fertilize and lay embryos)

d16

SWPCR of singled F2 hermaphrodite adults from d15
Again singled 8-10 F2 hermaphrodite adults (allowed to self-fertilize and lay
embryos)

d17

SWPCR of singled F2 hermaphrodite adults from d16
Selected worms from the homozygous mutant F2 hermaphrodite adult plates to
maintain 2x backcrossed mutant strain

Figure 6. Genotypes and ratios of outcrossed progeny in the 2x outcross of mutants of genes on
the X-Chromosome
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2x backcross for mutants balanced by a balancer strain
d1

Mutant hermaphrodite L4 (gfp) X
I
+
hT2g

N2 Male

III
mut
hT2g

d2

Singled mated mutant hermaphrodite adult

d5

F1 progeny (50% hermaphrodites; 50% males)
Non-gfp F1 male
I

III

+

mut
+

+
d6

(Cross I)

X

+

+

+

+

Balancer hermaphrodite L4
I
Dpy 5 unc-13
hT2g

(Cross II)

III
+
hT2g

Singled mated N2 hermaphrodite adults

d10
F1 progeny of Cross II
50% are non-viable; 25% are ‘dumpy’ (with no gfp) and out of the remaining 25%
that have gfp, half of them carry the mutant allele for acs-4 and the other half carry
the WT allele for acs-4. F1 hermaphrodites with gfp were singled and allowed to lay
eggs.
d11

SWPCR of F1 hermaphrodite adults that were allowed to lay eggs

d15

Singled 8-10 F2 hermaphrodites with gfp from heterozygous (gfp) F1
hermaphrodite adults and allowed to self-fertilize and lay eggs.

d16

50% of the F2 hermaphrodites are sterile, so do not have eggs on the plate. The
remaining 50% of F2s are heterozygous for acs-4(ok2872). The heterozygous F2s
are maintained by gfp as the 2x backcrossed strain.

Figure 7. Genotypes of F1 and F2 progeny in the 2x backcross of mutants of balanced mutant
strain: (acs-4(ok2872) III/hT2 [bli-4(e937) let-?(q782) qIs48] (I;III)

2.14

Behavioral assays on ethanol

Behavioral assays were performed to measure ethanol response of
backcrossed lf mutant strains and RNAi-fed worms.
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The detailed protocol for performing behavioral assays on ethanol is given in
Appendix I (Ethanol assay with copper rings). Approximately 24 hours before
the assay, 20 L4s of each strain to be assayed were picked onto a separate
seeded plate to get age-matched adults. NGM plates (unseeded) were dried
for 2 hours at 37°C and weighed. Four copper rings were heated in a flame
and were placed on the NGM agar in order to confine the worms to a small
area, which allows us to assay four strains of worms on a plate. Copper is
used for the rings because C. elegans are repelled by it. A volume of ice-cold
(refrigerated at 4°C) 100% ethanol corresponding to the plate weight (to
achieve a concentration of 400mM) was added (Appendix II, Table 18) to one
of the plates (400mM assay plate). The plate was immediately sealed with
Parafilm to prevent evaporation of ethanol and ethanol was allowed to
equilibrate for two hours. Another plate of approximately the same weight was
used as the ‘control’ 0mM assay plate. Two plates (for 0mM and 400mM)
were used for acclimation to starve worms for 30 minutes prior to placing
them on the assay plates. Each assay was performed with three strains of
mutant worms and N2 as control, with 10 worms of each strain placed in each
of the four copper rings. 2 minute time-lapse movies to track the locomotion of
worms on the assay plates (0mM and 400mM) were captured using the
ImagePro Plus software, at two different time points: 10 minutes and 30
minutes after worms were placed on the assay plates. The software captured
12-bit images of worms, one image per second, for 2 minutes (120 images),
which tracked the movement of worms within each copper ring. Analysis of
these assays was done using ImagePro Plus to obtain mean/average speeds
of worms within each copper ring, at different time points, at the two
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concentrations of ethanol (0mM and 400mM). In the analysis, the software
was used to analyze speed of individual worms from one second to the next
(over 120 seconds). The average velocity of each worm and the average
velocity of all worms within the ring was calculated by the software. This data
was exported into an excel file. The movies were recorded and analyzed as
detailed in Appendix I (Computer Tracking and Analyzing Movies). Paired ttests were performed on the mean/average speeds at the different time points
and concentrations of ethanol (from the locomotion assays) using GraphPad
Prism statistical software to determine initial sensitivity and acute tolerance of
the mutant strains to ethanol, in comparison to N2/the WT strain.
Since acute exposure to ethanol is known to have a depressive effect on
locomotion in C. elegans, we examined the following parameters using paired
t-tests: a) if the speeds of mutant and WT worms were significantly different in
terms of relative speeds at 10 minutes after exposure to ethanol (a measure
of initial sensitivity) b) if the relative speeds of each strain (mutant and WT)
were significantly different between 10 minutes and 30 minutes after exposure
to ethanol (a measure of development of AFT) and c) if the recovery
(difference between relative speeds at 10 minutes and 30 minutes of ethanol
exposure) of mutant strain was significantly different compared to the
recovery of WT strain.
These analyses helped us determine the ethanol responses in mutant strains;
whether the mutant strain was more or less sensitive to ethanol compared to
the WT strain and whether the recovery of mutant strain was more or less
than that of the WT strain. This allowed us to draw inferences about the
effects of target gene in ethanol response behavior.
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For all the 2x backcrossed mutant strains, ethanol assays were performed at
least four times (n=4) and among these, for the ones that did not show
significant difference in ethanol responses compared to N2, n=6 was done.
For the 6x backcrossed mutant strains, assays were done six times (n=6). All
the RNAi fed worms were assayed at least eight times (n=8), since RNAimediated gene knockdown is usually more variable compared to a mutant.
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3. RESULTS AND DISCUSSION

3.1 Candidate genes in mitochondrial beta-oxidation
As described in the Materials and Methods section, I began the candidate
gene selection by identifying all the genes involved in the pathway by
comparing the human and C. elegans mitochondrial beta-oxidation pathways.
Based on this comparison, I derived three sets of genes (listed in Table 7): (1)
genes from the C. elegans beta-oxidation pathway (2) C. elegans orthologs of
the human beta-oxidation genes, obtained using an ortholog prediction tool,
DIOPT v5.3 (DRSC Integrative Ortholog Prediction Tool) (Hu et al., 2011), (3)
all other genes within each family of enzymes catalyzing the mitochondrial
beta-oxidation pathway (for example, ACS family, ACDH family etc.,) that
were not included in the human or C. elegans mitochondrial beta-oxidation
pathways on KEGG.
Table 7. List of all genes reviewed. ‘On KEGG & DIOPT’ category includes the list of all
genes that were common between the two sets of genes obtained from C. elegans KEGG
mitochondrial beta-oxidation and the C. elegans genes that were found to be orthologs of
human mitochondrial beta-oxidation pathway, using DIOPT. ‘Only DIOPT’ category includes
the list of genes that were found to be orthologs of human mitochondrial beta-oxidation
pathway but not included in the C. elegans mitochondrial beta-oxidation pathway. ‘Only
KEGG’ category includes genes that were found in the C. elegans mitochondrial betaoxidation pathway but not found to be orthologs of human mitochondrial beta-oxidation
pathway, using DIOPT. ‘Neither’ category includes, genes that were members of the enzyme
families catalyzing mitochondrial beta-oxidation but were not included in either of the above
groups (KEGG or DIOPT).
On KEGG &
Only DIOPT
Only
Neither
DIOPT
KEGG
acs-3
acs-23
acs-2
acs-1
acs-4

cpt-6

acs-16

acs-5

W03F9.4

acs-7

acs-13

cpt-3

acs-8

acs-15

cpt-4

acs-9

acs-17

acdh-6

acs-10

acs-18

acdh-5

acs-11

cpt-1

acdh-2

acs-12

cpt-2

ech-7

acs-14
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acs-6

acdh-7

T02G5.4

acs-19

acdh-8

acs-20

acdh-10

acs-21

acdh-12

acs-22

acdh-1

cpt-5

acdh-3

acdh-9

acdh-4

acdh-11

F54D5.7

acdh-13

ech-1.1

ech-3

ech-1.2

ech-4

ech-6
ech-8
ech-9
B0272.3
F54C8.1
hacd-1
acaa-2
B0303.3
T02G5.7
kat-1
TOTAL NUMBER OF GENES IN EACH CATEGORY
29

10

2

19

We wanted to include the C. elegans orthologs of human mitochondrial betaoxidation genes because this pathway has not been extensively studied in
C. elegans, and hence it is possible that the roles of some C. elegans genes
have not yet been identified in mitochondrial beta-oxidation and these would
not be included in the pathway available on KEGG. There was some overlap
between these two gene sets i.e., some genes that were found in the
C. elegans mitochondrial beta-oxidation pathway were also orthologous to the
human mitochondrial beta-oxidation genes (see Figure 8). The third set of ‘all
other genes in each enzyme family’ was included to capture potential
candidate genes that have not been characterized in mitochondrial-betaoxidation and have also not been listed as orthologs to any of the human
mitochondrial beta-oxidation genes in DIOPT, but possess enzymatic activity
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in mitochondrial beta-oxidation (since they belong in the same family). These
three sets of genes were reviewed based on the previously defined exclusion
criteria, and the ones that could not be excluded were considered candidates.
We did not use inclusion criteria to select candidate genes for this project
because in order to have a strong basis for inclusion, these genes needed to
be well characterized for their role in beta-oxidation. But for most of these
genes there is little evidence implicating them in mitochondrial beta-oxidation.
Therefore, using inclusion criteria would result in exclusion of majority of these
genes due to lack of evidence. Lack of evidence does not mean that these
genes do not have a role in mitochondrial beta-oxidation. So, we used
exclusion criteria to make sure we did not miss any potential candidates due
to lack of evidence. Excluded genes are listed in Table 8, along with the
reason for exclusion for each gene. In retrospect, I am of the opinion that the
C. elegans orthologs of human short-chain ACS genes (ACSF, ACSS and
ACSM) should have been been included in the list of candidates. The reason
for this is that the C. elegans acs-2 gene is an ortholog of the human ACSF2
and acs-2 was found to have an effect on AFT in response to ethanol in
C. elegans. This implies that the other acs genes that are orthologs of human
short chain ACS genes could be potential candidates.
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C. elegans mitochondrial βoxidation (KEGG)

Human mitochondrial βoxidation (KEGG)
DIOPT

C. elegans
genes
orthologous to
human KEGG
genes (10)

29

C. elegans
KEGG genes
(2)

Figure 8. Mitochondrial beta-oxidation genes in C. elegans and humans. Two sets of genes were
obtained by comparing the human and C. elegans mitochondrial beta-oxidation pathway on KEGG
namely, C. elegans genes orthologous to human KEGG genes (that were determined using DIOPT,
ortholog prediction tool) and genes from the C. elegans mitochondrial beta-oxidation pathway on
KEGG.

Table 8. Reasons for exclusion of genes. This table contains a list of all genes that were
excluded along with the reasons for exclusion.
Gene
Reason for exclusion
acs-1
acs-6
acs-7
acs-8 (aka mec-18)
acs-9
acs-10
acs-11
acs-12
acs-14
acs-19
acs-20
acs-21
acs-23

Ortholog of ACSF2 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Ortholog of ACSS1 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Ortholog of ACSF2 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Irrelevant gene function – encodes protein similar to firefly luciferase.
Also expressed exclusively in touch cells. Unlikely to be involved in
mitochondrial beta-oxidation
Ortholog of ACSS1, ACSS3 and ACSM1, ACSM5 - none of these
genes are included in human KEGG pathway of mitochondrial betaoxidation
Ortholog of ACSS1 and ACSS2 – neither of these genes are
included in human KEGG pathway of mitochondrial beta-oxidation
Ortholog of ACSF3 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Ortholog of ACSF2 and several ACSM genes which are not included
in the human KEGG pathway of mitochondrial beta-oxidation
Ortholog of ACSF2 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Ortholog of ACSS2 which is not included in the human KEGG
pathway of mitochondrial beta-oxidation
Orthologs are FATP4 and several other solute carriers which are not
included in the human KEGG pathway of mitochondrial betaoxidation
Ortholog ACSF3, ACSF2 which are not included in the human KEGG
pathway of mitochondrial beta-oxidation
Annotated as psuedogene on wormbase
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acdh-9

acdh-13 (aka gei-9)
ech-8
ech-9
ech-3

Ortholog of ACAD8 and IVD - both of these are not included in the
human KEGG pathway of mitochondrial beta-oxidation - ACAD8
catalyzes catabolism of valine amino acid in mitochondria, IVD
catalyzes leucine catabolism; It is also annotated on KEGG as
isobutyryl-CoA dehydrogenase to be involved in Valine, leucine and
isoleucine degradation.
Ortholog of human ACOX1 and ACOX2. Both these acyl CoA
oxidases are involved in peroxisomal beta-oxidation of FA
Ortholog of human EHHADH (ECH and HADH), a bifunctional
enzyme that catalyzes peroxisomal beta-oxidation of FA
Ortholog of human EHHADH (ECH and HADH), a bifunctional
enzyme that catalyzes peroxisomal beta-oxidation of FA
Ortholog of ECI1, which is not included in the human KEGG pathway
of mitochondrial beta-oxidation. It is a peroxisomal auxillary enzyme
that catalyzes an isomerization step in the oxidation of unsaturated
fats.

Of the seven genes Dr. Alaimo tested, acs-2 and ech-6 lf exhibited significant
ethanol responses, so these were not included in the candidate genes list.
Among the remaining five genes he tested, I included ech-1.1 and ech-1.2 in
the list of candidate genes and excluded the other three (cpt-2, cpt-5 and ech4) based on my exclusion criteria.

Therefore, for the first aim, I performed a review on 60 genes in total (see
Table 7). I identified that 29 genes were common between the two gene sets
(see Figure 8), 2 genes were exclusively present in the C. elegans KEGG
pathway, 10 genes were obtained exclusively from DIOPT as orthologs of the
human mitochondrial beta-oxidation genes and 19 genes were found in
neither of the data sets, but reviewed because they were members of one of
the gene families catalyzing beta-oxidation. Out of these 60 genes, based on
the predetermined criteria, I excluded 18 genes (see Table 8). In total, I
excluded 23 genes (18 genes that I reviewed and excluded + two genes (acs2, ech-6) that Dr. Alaimo found to have a significant effect on ethanol
responses + three genes (cpt-2, cpt-5, ech-4) that Dr. Alaimo already tested
and I excluded). I considered the remaining 37 genes that could not be
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excluded to be bona fide candidates and ensured that at least one gene in
each step of the mitochondrial beta-oxidation pathway was included in these
candidates. lf mutant strains for 23 of the 37 candidate genes were available
and we ordered these strains from the CGC. For the other 14 genes we
decided to perform RNAi-mediated knockdown to test their role in ethanol
response.

3.2 Ethanol response phenotypes of candidate genes in mitochondrial betaoxidation
All the lf mutants and RNAi-mediated knockdown strains were assayed on
ethanol for behavioral responses. Twenty-one of the 23 lf mutant strains were
initially backcrossed twice (2x) and tested for their behavioral responses to
ethanol (the results for these assays are summarized in Table 9 and the
graphs are attached in Appendix III). Out of the 21 backcrossed mutants, 13
showed significantly different ethanol response phenotypes compared to WT
(N2) and eight of them were not different from N2 in their ethanol responses.
These eight strains were frozen and stored in the -80°C freezer. The 13
mutant strains that showed a significant difference were further backcrossed
to 6x to achieve ~98.375% WT background and eliminate other, not closely
linked, mutations, to ensure that the effect on ethanol response is likely to be
due to lf of the candidate gene. These 6x-backcrossed mutants were assayed
on ethanol to confirm the phenotypes observed in the 2x strains (the results
for these assays are summarized in Table 10 and the graphs are attached in
Appendix III). In five (acs-4, acs-13, acs-22, cpt-3 and T02G5.4) of the 13 6xbackcrossed mutants tested, ethanol responses (initial sensitivity and/or AFT)
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were no longer statistically significant in their difference from WT. A possible
reason for this is that the ethanol response phenotypes observed in the 2x
backcrossed strains could have been due to background mutations that were
eliminated in the 6x backcross. The remaining 14 candidate genes did not
have lf mutants available from the CGC, so we decided to perform RNAi to
knockdown the function of these genes and test them on ethanol. One of the
genes (cpt-1) was not available in the RNAi bacterial clones library (Ahringer,
Geneservice, Cambridge, UK), five of the RNAi clones did not grow in culture
and one RNAi clone did not carry the sequence of the target gene (acs-16).
Therefore, seven genes were knocked down using RNAi clones and the effect
of knockdown was tested on ethanol response (the results for these assays
are summarized in Table 10 and the graphs are attached in Appendix III).
Only two out of the seven RNAi genes (acdh-10, acdh-12) showed
significantly different responses to ethanol compared to the L4440 (empty
bacterial vector) treated worms. Since the effectiveness of RNAi across
experimental trials and across different genes is not consistent, it is important
to note that the lack of a significantly different ethanol response phenotype
does not rule out the remaining five genes as potential candidates that could
influence

ethanol
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responses.

Figure 9. Mitochondrial beta-oxidation of FA showing genes tested at each step of the pathway and their
ethanol response phenotypes: initial sensitivity (S) and AFT (T). The up (↑) arrow indicates more
sensitive (S) or increased development of AFT (T) compared to WT worms (N2 or L4440) and down (↓)
arrow indicates a less sensitive (S) or decreased AFT development (T) compared to WT worms. An
‘equal to’ (=) symbol indicates that the phenotype is not significantly different from that of WT worms.
Genes that appear to modulate either one of the ethanol responses are highlighted in bold. RNAi
knockdown genes are in gray font and lf mutants are in black font. Numbers in boxes
within each box of genes correspond to the following reaction steps, 1: Fatty acid
acyl CoA, catalyzed
by acyl CoA synthetases (ACS) 2: Transport of acyl CoA from cytosol to mitochondria, catalyzed by
carnitine palmitoyl transferases (CPT) 3: Acyl CoA
Trans-2-enoyl CoA, catalyzed by acyl CoA
dehydrogenases 4: Trans-2-enoyl CoA
3-hydroxy acyl CoA, catalyzed by enoyl CoA hydratases 5: 3hydroxy acyl CoA
3-keto acyl CoA, catalyzed by hydroxyl acyl CoA dehydrogenases 6: 3-keto acyl
CoA
acyl
CoA(n-2)
+
acetyl
CoA,
catalyzed
by
thiolases.
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acs-4(ok2872)

acs-3(gk826522)

N2 (10’):
40.61±2.75%

N2 (10’):
42.90±3.97%

N2 (10’):
35.48±2.78%

WT

acs-13 (10’):
49.68±2.67%

acs-5 (10’):
12.11±1.97%

acs-4 (10’):
25.90±2.87%

acs-3 (10’):
26.89±2.046%

Mutant

t6= 0.3281; P
= 0.7561

t4 = 12.36; P
= 0.0011

t6= 7.161; P
= 0.0008

t6= 5.596; P
= 0.0025

Initial Sensitivity (IS)

acs-5(ok2668)

N2 (10’):
35.48±2.78%

acs-17 (10’):
42.04±2.29%

t6= 0.1896; P
= 0.8571

t6= 6.565; P
= 0.0012

t6= 0.6544; P
= 0.5418

t4 = 0.74; P =
0.5148

t6= 0.6185; P
= 0.5633

t6= 2.513; P
= 0.0536

t6= 11.88; P
= 0.0013

IS not different from N2; AFT
not different from N2

IS not different from N2;
Reduced AFT than N2

IS not different from N2; AFT
not different from N2

Less sensitive than N2; AFT
not different from N2

More sensitive than N2; No
(significant) development of
AFT

More sensitive than N2; AFT
not different from N2

More sensitive than N2;
Reduced AFT than N2

Ethanol response
phenotypes

t8= 1.751; P
= 0.1234

Significance

Acute Functional Tolerance (AFT)
Mutant

acs-13(ok2861)

N2 (10’):
40.61±2.75%

acs-22 (10’):
38.35±2.16%

WT

acs-17(ok1562)

N2 (10’):
37.52±3.28%

Significance

acs-22(gk364606)

t6= 3.36; P =
0.0437

cpt-3(gk356297)*

t8= 2.095; P
= 0.0744

acs-3 (30’):
26.94±1.765%
acs-3 (10’-30’):
0.0400±0.52%
acs-4 (30’):
39.12±4.88%
acs-4 (10’-30’):
13.21±2.056
acs-5 (30’):
20.76±3.59%
acs-5 (10’-30’):
8.65±3.99%
acs-13 (30’):
64.31±3.05%
acs-13 (10’-30’):
14.63±2.76%
acs-17 (30’):
51.51±1.50%
acs-17 (10’-30’):
9.47±2.58%
acs-22 (30’):
44.59±3.00%
acs-22 (10’-30’):
6.23±1.61%
cpt-3 (30’):
56.10±2.15%
cpt-3 (10’-30’):
cpt-3 (10’):
43.93±2.50%

N2 (30’):
51.19±1.84%
N2 (10’-30’):
15.71±1.35%
N2 (30’):
59.30±4.71%
N2 (10’-30’):
16.39±2.11%
N2 (30’):
53.07±1.99%
N2 (10’-30’):
12.46±2.33%
N2 (30’):
51.19±1.84%
N2 (10’-30’):
15.71±1.35%
N2 (30’):
53.07±1.99%
N2 (10’-30’):
12.46±2.33%
N2 (30’):
54.22±3.97%
N2 (10’-30’):
16.71±2.33%
N2 (30’):
59.11±3.82%
N2 (10’-30’):
N2 (10’):
39.64±2.43%

Genotype

Table 9. Ethanol response phenotypes of 2x backcrossed loss of function (lf) mutants in the mitochondrial beta-oxidation pathway in C. elegans. The initial
sensitivity and AFT values in this table are the relative speeds of the worms at the 10 minute and 30 minute time points respectively. The (10’-30’) value for each
strain represents the difference in relative speeds between the 10 minute and 30 minute time points, which is a measure of the degree of recovery.

Step catalyzed

Fatty acid
Fatty acyl CoA
(ATP AMP)

Cytosolic acyl
CoA
Mitochondrial
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acyl CoA
(Transport)

Acyl CoA
Trans-2-enoyl
CoA
(FAD FADH2)

acdh-7(gk556025)

acdh-6(gk886629)

acdh-5(gk907299)

acdh-2(gk143151)

acdh-1(ok1514)

cpt-6(gk594576)

cpt-4(gk818803)*

N2 (10’):
31.15%±1.38
%

N2 (10’):
35.31±1.23%

N2 (10’):
35.31±1.23%

N2 (10’):
43.85±4.74%

N2 (10’):
31.15%±1.38
%

N2 (10’):
33.71±0.92%

N2 (10’):
39.64±2.43%

acdh-7 (10’):
45.37±3.46%

acdh-6 (10’):
41.53±2.01%

acdh-5 (10’):
36.08±1.53%

acdh-2 (10’):
43.80±3.85%

acdh-1 (10’):
42.17±3.03%

cpt-6 (10’):
33.71±4.44%

cpt-4 (10’):
37.97±2.96%

t6= 1.818; P
= 0.1287

t5= 3.345; P
= 0.0287

t6= 2.152; P
= 0.0840

t6= 0.3125; P
= 0.7673

t5= 0.008874;
P = 0.9933

t5= 2.857; P
= 0.0461

t4= 0.0010; P
= 0.9992

t8= 0.5597;
P = 0.5931

t4= 1.429; P

acdh-11 (10’):
39.24±1.43%

F54D5.7 (10’):

N2 (10’):
35.31±1.23%

N2 (10’):

acdh-11(gk753061)

F54D5.7(gk936057)
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N2 (30’):
59.11±3.82%
N2 (10’-30’):
19.47±4.07%
N2 (30’):
50.85±1.42%
N2 (10’-30’):
17.15±0.89%
N2 (30’):
48.12±1.40%
N2 (10’-30’):
16.96±1.44%
N2 (30’):
62.70±4.28%
N2 (10’-30’):
18.86±1.41%
N2 (30’):
52.20±1.58%
N2 (10’-30’):
16.89±0.70%
N2 (30’):
52.20±1.58%
N2 (10’-30’):
16.89±0.70%
N2 (30’):
48.12±1.40%
N2 (10’-30’):
16.96±1.44%
N2 (30’):
52.20±1.58%
N2 (10’-30’):
16.89±0.70%

19.47±4.07%

cpt-4 (30’):
49.66±5.29%
cpt-4 (10’-30’):
11.70±3.16%
cpt-6 (30’):
48.94±2.45%
cpt-6 (10’-30’):
15.23±2.11%
acdh-1 (30’):
55.29±1.14%
acdh-1 (10’-30’):
13.12±2.06%
acdh-2 (30’):
49.46±4.18%
acdh-2 (10’-30’):
5.66±0.54%
acdh-5 (30’):
51.88±2.35%
acdh-5 (10’-30’):
15.80±1.18%
acdh-6 (30’):
57.13±1.91%
acdh-6 (10’-30’):
15.60±0.42%
acdh-7 (30’):
53.97±1.38%
acdh-7 (10’-30’):
8.59±2.47%
acdh-11 (30’):
59.68±2.33%
acdh-11 (10’30’):
20.44±1.71%
F54D5.7 (30’):

12.17±2.30%

N2 (30’):

t4= 1.050; P

t6= 1.593; P
= 0.1720

t5= 3.090; P
= 0.0366

t6= 2.132; P
= 0.0862

t6= 0.6510; P
= 0.5438

t5= 8.252; P
= 0.0012

t5= 2.101; P
= 0.1036

t4= 1.446; P
= 0.2440

t8= 1.348; P
= 0.2211

IS not different from N2; AFT

IS not different from N2; AFT
not different from N2

Less sensitive than N2;
Reduced AFT than N2

IS not different from N2; AFT
not different from N2

IS not different from N2; AFT
not different from N2

IS not different from N2;
Reduced AFT than N2

Less sensitive than N2; AFT
not different from N2

IS not different from N2; AFT
not different from N2

IS not different from N2; AFT
not different from N2

Trans-2-enoyl
CoA
3hydroxy acyl
CoA
3-hydroxy acyl
CoA
3-keto
acyl CoA
(NAD+ NADH)
3 keto acyl
CoA
Acetyl
CoA (+
shortened fatty
acyl CoA)

t8= 0.1110; P
= 0.9147

= 0.2483

N2 (30’):
59.11±3.82%
N2 (10’-30’):
19.47±4.07%

50.85±1.42%
N2 (10’-30’):
17.15±0.89%

47.75±10.01%

t6= 0.3159; P
= 0.7648

33.71±0.92%

hacd-1 (10’):
36.23±2.15%

ech-1.2 (10’):
39.30±1.05%

N2 (10’):
37.52±3.28%

t5= 3.472; P
= 0.0255

N2 (10’):
39.64±2.43%

hacd-1(ok2776)

T02G5.4 (10’):
40.26±1.86%

ech-1.2(gk527451)*

T02G5.4(ok3160)

N2 (30’):
54.22±3.97%
N2 (10’-30’):
16.71±2.33%
N2 (30’):
48.12±1.40%
N2 (10’-30’):
16.96±1.44%
t4= 1.926; P
= 0.1498

N2 (30’):
50.85±1.42%
N2 (10’-30’):
17.15±0.89%

N2 (10’):
31.15%±1.38
%
T02G5.7 (10’):
37.39±2.24%

t6= 2.010; P
= 0.1006

N2 (10’):
33.71±0.92%

N2 (10’):
40.61±2.75%

N2 (30’):
53.07±1.99%
N2 (10’-30’):
12.46±2.33%

T02G5.7(ok3574)

acaa-2(ok1978)

acaa-2
(10’):46.73±2.
21%
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55.68±2.18%
F54D5.7 (10’30’):
7.93±9.61%
ech-1.2 (30’):
46.95±2.182%
ech-1.2 (10’30’):
7.650±1.86%
hacd-1 (30’):
49.35±1.70%
hacd-1(10’-30’):
13.12±1.46%
T02G5.4 (30’):
62.17±3.42%
T02G5.4 (10’30’):
21.91±3.42%
T02G5.7 (30’):
55.56±2.57%
T02G5.7 (10’30’):
18.17±1.57%
acaa-2 (30’):
54.37±1.29%
acaa-2 (10’-30’):
7.64±1.83%

t6= 2.576; P
= 0.0496

t4= 0.4682; P
= 0.6715

t5= 1.279; P
= 0.2701

t6= 2.007; P
= 0.1010

t8= 3.077; P
= 0.0179

= 0.3070

Less sensitive than N2; AFT
not different from N2

IS not different from N2; AFT
not different from N2

Less sensitive than N2; AFT
not different from N2

IS not different from N2; AFT
not different from N2

IS not different from N2;
Reduced AFT than N2

not different from N2

Initial Sensitivity (IS)

Significance

Ethanol response
phenotypes
Mutant

Acute Functional Tolerance (AFT)
WT

Mutant

Significance

WT

IS not different from N2; No
development of AFT

acs-3 (10’):
32.18±2.65%

t6= 0.1438; P =
0.8913

t6= 11.32; P <
0.0001

N2 (10’):
34.81±2.17%
acs-4 (10’):
35.60±5.49%

t6= 0.9188; P =
0.4003

acs-3(gk826522)

N2 (10’):
35.04±2.03%

IS not different from N2;
AFT not different from N2

acs-4(ok2872)

t6= 0.8301; P =
0.4443

acs-5(ok2668)

t6= 5.336; P =
0.0031

More sensitive than N2;
Reduced development of
AFT

acs-5 (10’):
16.03±1.99%

t6 = 1.214; P =
0.2788

t6= 10.34; P =
0.0001

N2 (10’):
30.75±2.61%

acs-13 (10’):
37.88±4.24%

IS not different from N2;
AFT not different from N2

N2 (10’):
30.75±2.61%

t6= 1.707; P =
0.1486

t6 = 0.7020; P =
0.5140

acs-13(ok2861)

acs-22 (10’):
38.47±3.45%

IS not different from N2;
AFT not different from N2

N2 (10’):
30.75±2.61%

t6= 1.369; P =
0.2293

t6= 1.937; P =
0.1104

acs-22(gk364606)

cpt-3 (10’):
38.50±3.44%

IS not different from N2;
AFT not different from N2

N2 (10’):
34.77±1.80%

t6= 1.074; P =
0.3319

cpt-3(gk356297)

IS not different from N2;

t6= 0.1537; P =

t6= 3.777; P =

cpt-4 (10’):

acs-3 (30’):
33.51±2.97%
acs-3 (10’-30’):
1.33±1.23%
acs-4 (30’):
50.81±5.27%
acs-4 (10’-30’):
15.21±3.76%
acs-5 (30’):
19.23±1.50%
acs-5 (10’-30’):
3.21±0.83%
acs-13 (30’):
66.50±23.73%
acs-13 (10’-30’):
28.62±19.93%
acs-22 (30’):
47.11±3.12%
acs-22 (10’-30’):
8.64±2.62%
cpt-3 (30’):
47.32±2.99%
cpt-3 (10’-30’):
8.817±1.698%
cpt-4 (30’):
N2 (10’):

N2 (30’):
47.03±1.96%
N2 (10’-30’):
12.22±1.45%
N2 (30’):
47.30±2.14%
N2 (10’-30’):
12.27±1.06%
N2 (30’):
45.27±2.24%
N2 (10’-30’):
14.53±1.18%
N2 (30’):
45.27±2.24%
N2 (10’-30’):
14.53±1.18%
N2 (30’):
45.27±2.24%
N2 (10’-30’):
14.53±1.18%
N2 (30’):
45.15±3.15%
N2 (10’-30’):
10.38±1.90
N2 (30’):
cpt-4(gk818803)

Genotype

Table 10. Ethanol response phenotypes of 6x backcrossed lf mutants and RNAi knockdown strains in mitochondrial beta-oxidation pathway in C. elegans. The initial sensitivity
and AFT values in this table are the relative speeds of the worms at the 10 minute and 30 minute time points respectively. The (10’-30’) value for each strain represents the
difference in relative speeds between the 10 minute and 30 minute time points, which is a measure of the degree of recovery. (Note: For all the 6x backcrossed mutants, the N2s
used as WT for the behavioral assays are different from the N2s used for the backcrossing. In the lab, it is standard practice to thaw out and use a new stock of N2 worms once a
year or every few months since it is possible that the N2 strain being maintained in the lab accumulates genetic mutations over time and is no longer ‘WT’).
Step catalyzed

Fatty acid
Fatty acyl CoA
(ATP AMP)

Cytosolic acyl
CoA
Mitochondrial
acyl CoA
(Transport)
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Acyl CoA
Trans-2-enoyl
CoA
(FAD FADH2)
acdh-2(gk143151)

acdh-1(ok1514)

W03F9.4 (RNAi)

N2 (10’):
32.31±2.22%

N2 (10’):
32.31±2.22%

L4440 (10’):
31.99±2.41%

36.74±2.46%

acdh-2 (10’):
45.30±1.52%

acdh-1 (10’):
51.05±3.62%

W03F9.4
(10’):
31.25±2.71%

37.14±0.50%

t6= 4.076; P =
0.0096

t6= 3.945; P =
0.0109

t8= 0.2630; P =
0.8002

0.8838

t6= 1.573; P =
0.1766

acdh-4 (RNAi)

acdh-7 (10’):
38.92±4.05%

t8= 1.650; P =
0.1428

N2 (10’):
32.31±2.22%

acdh-4 (10’):
33.90±4.36%

acdh-7(gk556025)

L4440 (10’):
28.54±1.69%

acdh-8 (RNAi)

t8= 1.357; P =
0.2169

t8= 6.182; P =
0.0005

acdh-8 (10’):
30.03±2.46%

acdh-10
(10’):
38.72±1.89%

L4440 (10’):
28.46±1.93

acdh-10 (RNAi)

L4440 (10’):
29.19±1.76%
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47.65±2.08%
N2 (10’-30’):
10.91±0.76%
L4440 (30’):
42.83±2.09%
L4440 (10’30’):
10.84±2.09%
N2 (30’):
46.80±2.27%
N2 (10’-30’):
14.10±0.87%
N2 (30’):
46.80±2.27%
N2 (10’-30’):
14.10±0.87%
L4440 (30’):
44.09±2.11%
L4440 (10’30’):
15.56±1.38%
N2 (30’):
46.80±2.27%
N2 (10’-30’):
14.10±0.87%
L4440 (30’):
44.35±2.15%
L4440 (10’30’):
15.89±1.34%
L4440 (30’):
43.94±2.14%
L4440 (10’30’):
14.75±1.22%

54.32±0.87%
cpt-4 (10’-30’):
17.18±1.01%
W03F9.4 (30’):
45.18±3.42%
W03F9.4 (10’30’):
13.92±2.51%
acdh-1 (30’):
59.29±2.13%
acdh-1 (10’-30’):
8.24±3.65%
acdh-2 (30’):
53.32±2.78%
acdh-2 (10’-30’):
8.02±2.89%
acdh-4 (30’):
48.66±4.91%
acdh-4 (10’-30’):
14.76±2.726%
acdh-7 (30’):
43.98±3.31%
acdh-7 (10’-30’):
5.065±2.83%
acdh-8 (30’):
46.53±2.78%
acdh-8 (10’-30’):
16.50±1.46%
acdh-10 (30’):
50.20±2.14%
acdh-10 (10’30’):
11.48±1.00%

t8= 2.788; P =
0.027

t6= 0.3235; P =
0.7557

t6= 3.510; P =
0.0171

t8= 0.3117; P =
0.7644

t6= 2.525; P =
0.0529

t6= 2.222; P =
0.0770

t8= 1.370; P =
0.2130

0.0129

Less sensitive than L4440;
Reduced AFT than L4440

IS not different from L4440;
AFT not different from
L4440

IS not different from N2;
Reduced AFT than N2

IS not different from L4440;
AFT not different from
L4440

IS not different from N2;
Reduced AFT than N2

Less sensitive than N2;
AFT not different from N2

IS not different from L4440;
AFT not different from
L4440

Higher development of AFT
than N2

Trans-2-enoyl
CoA
3-hydroxy
acyl CoA

3 keto acyl CoA
Acetyl CoA (+
shortened fatty
acyl CoA)

acdh-12 (RNAi)

t8= 3.039; P =
0.0189

t8= 1.133; P =
0.2946

acdh-12
(10’):
39.10±2.34%

ech-1.1 (10’):
36.90±4.23%

t6= 2.427; P =
0.0596

L4440 (10’):
31.05±2.69%

L4440 (10’):
31.05±2.69%

T02G5.4
(10’):
43.60±2.44%

t6= 4.066; P =
0.0097

t6= 1.457; P =
0.2048

ech-1.1 (RNAi)

N2 (10’):
34.77±1.80%

acaa-2 (10’):
39.09±2.17%

ech-1.2 (10’):
43.60±3.69%

T02G5.4(ok3160)

N2 (10’):
34.77±1.80%

t6= 0.2232; P =
0.8298

N2 (10’):
36.74±2.46%

acaa-2(ok1978)

B0303.3
(10’):
29.75±2.86%

ech1.2(gk527451)

B0303.3 (RNAi)

L4440 (10’):
30.24±3.03%
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L4440 (30’):
44.07±2.47%
L4440 Rec
(10’-30’):
13.02±1.19%
N2 (30’):
47.65±2.08%
N2 (10’-30’):
10.91±0.76%
L4440 (30’):
44.07±2.47%
L4440 (10’30’):
13.02±1.19%
N2 (30’):
45.15±3.15%
N2 (10’-30’):
10.38±1.90%
N2 (30’):
45.15±3.15%
N2 (10’-30’):
10.38±1.90%
L4440 (30’):
44.74±2.50%
L4440 (10’30’):
14.51±1.51%

acdh-12 (30’):
54.16±2.94%
acdh-12 Rec
(10’-30’):
15.07±2.41%
ech-1.2 (30’):
56.02±4.38%
ech-1.2 (10’30’):
3.63±1.56%
ech-1.1 (30’):
52.39±4.85%
ech-1.1 (10’30’):
15.49±3.59%
T02G5.4 (30’):
55.79±4.36%
T02G5.4 (10’30’):
12.19±2.78%
acaa-2 (30’):
52.28±2.91%
acaa-2 (10’-30’):
13.19±1.89%
B0303.3 (30’):
44.48±3.54%
B0303.3 (10’30’):
14.74±1.82%

t6= 0.1214; P =
0.9067

t6= 0.9148; P =
0.4023

t6= 0.5017; P =
0.6372

t8= 0.5919; P =
0.5726

t6= 5.824; P =
0.0021

t8= 0.7977; P =
0.4512

IS not different from L4440;
AFT not different from
L4440

Less sensitive than N2;
AFT not different from N2

IS not different from N2;
AFT not different from N2

IS not different from L4440;
AFT not different from
L4440

IS not different from N2;
Reduced AFT than N2

Less sensitive than L4440;
AFT not different from
L4440

3.3

Ethanol affects mitochondrial beta-oxidation

A search on NCBI (PubMed Central) for ‘mitochondrial beta-oxidation AND
ethanol’ gives 13325 results, 8226 of them published in the last five years. A
majority of studies examines the effects of alcohol/ethanol on mitochondrial
function, particularly in hepatocytes, since the liver is the primary site for
alcohol metabolism. Several research groups have also dissected the
molecular

mechanisms

underlying

mitochondrial

dysfunction

in

neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease and alcoholic dementia (Akbar et al., 2016; Srivastava et
al., 2010).

Ethanol has been found to cause mitochondrial dysfunction, damage to
mitochondrial DNA and inhibition of mitochondrial beta-oxidation of FA.
Ethanol also affects oxidative phosphorylation and electron transport chain
processes in the mitochondria. The focus has been on the role of
mitochondria in progression of alcoholic liver diseases (ALD) and its
usefulness as a therapeutic target for ALD (Apostolova & Victor, 2015; King et
al., 2016). Mitophagy has been found to prevent cell death in alcohol-induced
liver injury by removing damaged mitochondria that are unable to perform
beta-oxidation of FA (Ding et al., 2011).

Andringa et al., (2010) used Male Sprague-Dawley rats to analyze the effect
of ethanol on the liver mitochondria proteome. They pair fed these rats a
control diet and an ethanol-containing diet for at least 31 days and then
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performed a series of experiments to look at how mitochondrial proteins
respond to alcohol exposure. They extracted and separated mitochondrial
proteins by isoelectric focusing followed by gel electrophoresis. The 2D gel
image analysis of these mitochondrial proteins showed that 30 of the 76
proteins examined were altered in abundance in response to ethanol. Using
mass-spectrometry analysis, they identified these proteins and grouped them
into four functional classes, one of them being mitochondrial-beta-oxidation.
They determined that several enzymes involved in mitochondrial betaoxidation, long-chain ACDH, ECH and long-chain HADH, were significantly
decreased in the alcohol-fed rats compared to controls.

To assess the effect of ethanol on mitochondrial outer membrane (MOM)
permeability Holmuhamedov & Lemasters (2009) incubated isolated rat
hepatocytes with ethanol and exposed the cells to a low concentration of
digitonin, which selectively permeabilizes the plasma membrane to allow entry
of adenine nucleotides and exogenous respiratory substrates like succinate.
They measured oxygen consumption and adenylate kinase activity before and
after digitonin treatment and found that ethanol pretreatment decreased
succinate-supported respiration. Also, MOM permeabilization with high
digitonin overcame the effects of ethanol and restored respiration and
adenylate kinase activity. Moreover, high digitonin treatment of untreated
hepatocytes did not change the rate of succinate-supported respiration or
adenylate kinase activity. These results suggested that MOM permeability to
hydrophilic metabolites decreases after ethanol treatment. Since voltage
dependent anion channel (VDAC) is the only channel known to allow
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hydrophilic metabolites to cross the outer membrane of the mitochondria in
normal viable cells, they hypothesized that ethanol-induced decrease of
mitochondrial outer membrane permeability could be through inhibition of
VDAC.

In another study performed in cultured rat hepatocytes, Bailey et al., (1999)
found that ethanol decreased mitochondrial FA oxidation and production of
ATP. They hypothesized that this could be through the inhibition of the
conductance of VDAC in the mitochondrial outer membrane since VDAC is
essential for maintaining the permeability of outer mitochondrial membrane to
molecules that are necessary for beta-oxidation such as ATP, ADP and fatty
acyl CoA. Bailey and Cunningham (1998) found that ethanol also altered
cellular energy balance, which plays a role in beta-oxidation. Specifically, they
found that in isolated hepatocytes, acute ethanol exposure increased the
cellular NADH/NAD+ ratio, which would be predicted to inhibit mitochondrial
beta-oxidation, as it is an allosteric regulator of the pathway. They
hypothesized that this increase could be due to increase in production of
mitochondrial reactive oxygen species (ROS) (Bailey et al., 1999). Thus, it is
clear that ethanol affects various biological pathways occurring in the
mitochondria, and that mitochondrial beta-oxidation of FA is one of them.

While the effects of ethanol on mitochondrial function and beta-oxidation of
FA has been well studied, there has not been much research on how the
various components of beta-oxidation in mitochondria affect ethanol
metabolism and its effects on the organism. For the purpose of this project,
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we were particularly interested in examining whether mitochondrial betaoxidation has a role in neuronal responses to ethanol exposure. We tested
genes at every step of mitochondrial beta-oxidation. Our results from
behavioral assays of lf mutants and RNAi knockdown strains indicate that
there is certainly more than one step or enzyme or reaction component of the
pathway that is involved in mediating this effect.

It is important to keep in mind while interpreting this data that (1) a majority of
the enzymes catalyzing this pathway exhibit chain-length specificity (2) there
are several aspects of beta-oxidation that have diverse physiological
functions, like free fatty acids (FFA, the first substrate of beta-oxidation),
energy transfers that occur during beta-oxidation, and intermediate products
like fatty acyl CoA. Long chain FFA increase mitochondrial permeability,
uncouple oxidative phosphorylation and inhibit ATP synthesis while nonesterified FA are metabolized into diacyl glycerol (DAG) (Wojtczak &
Schonfeld, 1993). Acyl CoA derivatives inhibit tricarboxylic acid (TCA) cycle
and also competitively inhibit activation of pyruvate carboxylate, which is an
enzyme involved in gluconeogenesis. Acyl CoA also plays a role in synthesis
of polar and neutral lipids, and TAGs. The functions of these components of
beta-oxidation are discussed in detail in subsequent paragraphs.

3.4 Acyl CoA Synthases (ACS)
Acyl CoA synthases (ACS) catalyze the first step of mitochondrial betaoxidation, converting FA to fatty acyl CoA (Figure 9). We examined seven
acs-family genes including acs-2, which was previously tested by Dr. Alaimo
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(see Introduction) and three of the lf mutant strains showed a significantly
different ethanol response phenotype. acs-2 displayed reduced AFT
compared to WT but did not differ significantly in initial sensitivity. acs-3
mutants did not develop AFT in response to ethanol, but were not significantly
different from WT in terms of initial sensitivity. acs-5 showed reduced AFT
development and increased sensitivity in response to ethanol compared to
WT worms. acs-4, acs-13, acs-17 and acs-22 lf strains showed ethanol
responses similar to WT. At the 2x backcrossed stage, acs-4, acs-13 and acs22 also showed a significant ethanol response phenotypes, but the
significance of this was lost when backcrossed to 6x. This may not be
surprising, because by backcrossing we are eliminating possible background
mutations. So, it is possible that the phenotypes are less robust in the 6xbackcrossed strain of certain mutants compared to their 2x-backcrossed
strain which implies that the ethanol response phenotypes observed in the 2xbackcrossed mutants could have been due to the effect of background
mutations in the mutant strains.

Disruption of the esterification or activation of FA to fatty acyl CoA would lead
to an increase in the levels of FFA and decrease in acyl CoA. FFA, which are
the first substrate in the beta-oxidation of FA, have diverse physiological
functions. Among their functions is a role in the activation of protein kinase C
(PKC) in different cells or organs (Boneh, 1996). PKC is a family of enzymes
that activate or regulate other proteins by phosphorylation of hydroxyl groups
on the serine and threonine residues of the target proteins. One member of
this family is the PKCγ, which is solely expressed in the brain and spinal cord.
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It is activated by Ca+2, phosphatidylserine and DAGs. PKCγ is also activated
by unsaturated FA, with the extent of activation being proportional to the
degree of unsaturation (Nishizuka, 1992). Studies have shown that γaminobutyric acid A (GABAA) receptors in the brain of PKCγ-deficient mice do
not respond to ethanol, and the PKCγ-deficient mice show a reduced
sensitivity to acute ethanol (measured using righting reflex and body
temperature). Saito & Shirai (2002) suggested that PKCγ modulates the
sensitivity of

GABAA

receptors to

ethanol. GABA

is an inhibitory

neurotransmitter and GABAA is a class of GABA receptors. It has been shown
in numerous research studies that ethanol potentiated GABA A mediated
current, which increased the action of GABA at these receptors (Davies,
2003). Breaking down the hypothesis of Saito & Shirai, in the absence of
PKCγ the GABAA receptors would not be potentiated by ethanol and therefore
there would be decreased/no action of GABA at these receptors. This in turn,
would result in decreased inhibitory action of GABA on the nervous system,
which would explain the reduced sensitivity of PKCγ-deficient mice to acute
ethanol. Applying these findings to the ethanol response phenotype we saw in
some of the acs mutants (acs-3, acs-4 and acs-5 showed increased sensitivity
to ethanol, and acs-5 showed reduced development of AFT), I hypothesize
that lack of ACS activity in these mutants would lead to the buildup of FFA.
This could increase activation of PKCγ, which, in turn, could lead to increased
sensitivity to ethanol compared to the WT worms in which there is
comparatively less amount of FFA. To test this hypothesis, we could create
and test a double mutant of pkc-2;acs-5 (that has lf in pkc-2, which is the
PKCγ in C. elegans and acs-5) for ethanol responses. We could then express
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pkc-2 specifically in the neurons expressing GABAA receptors in the double
mutants using the promoter of unc-49. The reason for creating a pkc-2(lf)
specifically in these neurons is to make sure that the effect of pkc-2(lf) on
ethanol response phenotypes we expect to see would not be confounded by
potential action of PKC through other neurotransmitter receptors. If lack of
acs-5 activity is indeed modulating sensitivity to ethanol through PKC
activation and GABA, we would expect the sensitivity of the pkc-2;acs-5 lf
double mutant to be lower than that of the acs-5(lf), since there is no PKC for
the FFA to activate and therefore, no potentiation of GABA.

FFA have also been found to affect neurotransmitter receptors; particularly
neuronal nicotinic acetylcholine receptors (nAChRs) in various in vitro and in
vivo models, but the results from these studies are conflicting (Albuquerque et
al., 2009; Antollini & Barrantes, 2016) showed that FFAs had an inhibitory
effect on nAChR. Ikeuchi et al., 1996 suggested that the effects of FA on
nAChRs vary across species, possibly due to the differences in receptor
subunit structure and composition in various organisms. They saw a
potentiation effect of arachidonic acid (AA), a PUFA, on Torpedo nAChR
expressed in Xenopus oocytes and treatment of chick α7 nAChR with AA
caused a depression effect while treatment of rat α7 nAChR caused
exclusively a potentiation effect by PKC activation.

α7 nAChRs have also been extensively studied in understanding the
mechanism of ethanol’s action on the brain. McDaid et al., 2016 tested effects
of ethanol on α7 nAChRs using brain sections of male Sprague Dawley rats.
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They performed electrophysiological studies to measure nAChR-mediated
currents, on isolated sections containing laterodorsal tegmental nucleus
(LDTg), where the α7 receptors are expressed abundantly. They found that
pretreatment with 25mM ethanol for 10 minutes inhibited α7 nAChR currents
significantly. Yu et al., (1996) using α7 nAChRs expressed in Xenopus
oocytes, looked at the effect of ethanol on these receptors. Their
electrophysiological recordings of nAChR currents using two-electrode
voltage clamp, revealed that application of ethanol inhibited α7 nAChR
currents in a concentration-dependent manner over a concentration range of
5-100 mM ethanol. Studies in cultured rat cortical neurons showed that
ethanol potentiated non-α7 nAChR- but inhibited α7 nAChR-mediated
currents. In Xenopus oocytes, ethanol at low concentrations inhibited α7
nAChR currents but potentiated α2β4, α4β4, α2β2, and α4β2 nAChRs at
higher concentrations (Wu et al., 2014). Seeing that the α7 nAChR has been
widely studied in the context of FFA and neuronal effect of ethanol, I consider
it as an ideal candidate to pursue for future experiments.

Based on the evidence discussed above, I propose a model to test if the
effect of acs lf on ethanol responses acts through regulation of α7 nAChR by
FFA. In C. elegans, acr-16 codes for a α7-like subunit of nAChR, which is
orthologous to the human nAChR α7 (sharing 81.7% protein sequence
identity). An acr-16 mutant was tested by Patraic Lichtman (a student in the
Davies-Bettinger lab) for effects on ethanol response phenotypes and he
found that this mutant is resistant to ethanol (decreased sensitivity compared
to N2), which supports previous findings that ethanol could be acting through
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inhibition of α7 nAChR. Lf mutants of acs-3, acs-4 and acs-5 showed
increased sensitivity to ethanol. If the effect of loss of acs function on
sensitivity is due to action of FFA on ACR, I hypothesize that, a double mutant
of acs-5;acr-16 lf assayed on ethanol would display decreased initial
sensitivity compared to acs-5 lf mutants. acs-5 lf would increase concentration
of FFA, but due to lf in acr-16, the FFA would be unable to potentiate the α7like receptor, due to which I predict that the initial sensitivity would be
decreased compared to the acs-5 mutant.

We can see that while acs-5(lf) results in increased initial sensitivity, acs-2,
acs-3 and acs-5 appear to be important for AFT, since worms carrying
deletions in these genes exhibit reduced AFT relative to N2. A possible
reason for the varying effects of different acs genes on the two ethanol
responses phenotypes could be that each of these enzymes catalyzes
esterification of FA for different pathways, and some of these pathways might
affect only one of the two ethanol response components we are studying. For
example, loss of acs-2 function affects tolerance but not sensitivity and loss of
acs-4 affects sensitivity, not AFT. On the other hand, acs-22, acs-17 and acs13 lf do not have any effect on either sensitivity or AFT to ethanol. From
studying human ACS genes, we know that each member of the ACS family
preferentially catalyzes the esterification of specific chain lengths of FA and
directs the FA-CoAs into different downstream processes (Figure 10).
Therefore, it is possible that these acs-genes partition the acyl CoA into
downstream pathways that vary in their effects on ethanol response behavior.
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Since there has not been very extensive research conducted on worm ACS
enzymes, we used evidence from human (cell culture studies) and mouse
models looking at the orthologs of these worm genes to understand the
various pathways into which acyl CoAs are partitioned by the different ACS
genes (Table 11).
Table 11. Human and Mouse orthologs of acs genes tested for ethanol responses.
acs genes in C.
elegans

Human Ortholog

Mouse Ortholog

acs-2

ACSF2

ACSF2

acs-4 & acs-17

ACSL3/ACS3
ACSL4/ACS4

ACSL3
ACSL4

ACSL1
ACSL5
ACSL6

ACSL5

SLC27A1 (FATP1)
SLC27A2 (FATP2)
SLC27A3
(FATP3)
SLC27A4 (FATP4)
SLC27A5 (FATP5)
SLC27A6 (FATP6)

SLC27A1 (FATP1)
SLC27A2 (FATP2)
SLC27A4 (FATP4)
SLC27A5 (FATP5)

acs-5, acs-3
acs-13
acs-22

&

As briefly discussed in the Introduction, ACS enzymes catalyze the
activation/esterification of FFA into fatty acyl CoA in an ATP-dependent
reaction. The fatty acyl CoA produced can enter the mitochondrial matrix
(long-chain FA-CoAs require carnitine for transport while short and mediumchain FA-CoAs can directly enter the matrix), or can become involved in a
variety of

other biological processes including synthesis of

TAGs,

sphingolipids, phospholipids, protein acetylation and transcriptional regulation
of gene expression (Watkins & Ellis, 2012).
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The Coleman group has been studying ACS enzymes for several years using
a combination of in vitro overexpression in rat cell lines and in vivo knockout
mouse models. They have characterized the structure, tissue localization
(Mashek et al., 2007) and physiological functions various ACS family
members (Cooper et al., 2015). Their experiments using broad and specific
inhibitors of ACS enzymes revealed that both ACS1, which is expressed in
heart, liver and adipose tissues, and ACS2, a brain-specific subtype, exhibit
broad substrate specificity and show structural similarity. ACS3 is highly
expressed in brain and uses laurate and myristate most efficiently among the
C8–C22 saturated FA and arachidonate and eicosapentaenoate among the
C16–C22 unsaturated FA. ACS4 shows a preference for arachidonate and
eicosapentaenoate (PUFAs) and C14-C22 unsaturated FA, and exhibits a low
affinity for palmitate (Kang et al., 1997). Also, the Coleman group showed that
specific inhibition of ACS1 and ACS4 suggested that they are involved in
triacylglycerol synthesis and de novo synthesis of phospholipids and
phospholipid reacylation. This also suggested that oxidation must rely on acylCoA synthesized by other isoforms (Coleman et al., 2002).
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Figure 10. Inhibitors suggest possible products of acyl-CoA produced by ACS
isoforms. Coleman et al., (2002) used two inhibitors, Triascin C (a fungal-derived competitive
inhibitor of ACS) and Troglitazone, a thiazolidinedione (TZD), which selectively inhibits some
pathways catalyzed by ACS enzymes. Triascin C was found to inhibit ACS1 and ACS4, but
not ACS5, and TZD inhibited only ACS4. Using labeled FA of different chain lengths and
recombinant expression of specific rat ACS isoforms in E. coli expression vectors, it was
found that Triascin C inhibited the incorporation of [3H]glycerol into phospholipid and
triacylglycerol, in human fibroblasts and also blocked Incorporation of [ 14C]oleate into
triacylglycerol in rat hepatocytes. Abbreviations: ACS, acyl-CoA synthetase; CE, cholesteryl
ester; PL, phospholipid; TAG, triacylglycerol; TZD, thiazolidinedione. Reused with permission
from “Do Long-Chain Acyl-CoA Synthetases Regulate Fatty Acid Entry into Synthetic Versus
Degradative Pathways?”, by R.A. Coleman, et al., 2002, The Journal of Nutrition, 132 (8),
p.2123. Copyright 2002, by The American Society for Nutritional Sciences.

Therefore, the ideal next step in identifying specific mechanisms through
which these acs genes could be acting to modulate responses to ethanol,
would be to characterize genes within each of these downstream pathways
and test candidates that could give the most information about the role of that
pathway in ethanol response (by choosing a gene that codes for an enzyme
that is essential and exclusive for that particular pathway). For example,
glycerol-3-phosphate acyl transferase (GPAT) is the enzyme catalyzing the
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first step of phospholipids from glycerol-3-phosphate and a saturated acyl
CoA, which forms lyophosphatidic acid. This is followed by addition of a
second

acyl

CoA

by

acylglycerol-3-acyltransferase

(AGPAT)

to

lyophosphatidic acid to form phosphatidic acid, which then is metabolized into
DAG, TAG and other phospholipids like phosphatidyl inositol and phosphatidyl
choline. GPAT acts in the outer mitochondrial membrane and AGPAT acts in
the ER (Wendel et al., 2009). Using genetic mutants that block these two
pathways that are essential for phospholipid, DAG and TAG synthesis could
be a useful first step in narrowing down the possible mechanisms through
which acyl CoA could be affecting ethanol response phenotypes. In
C. elegans, acl-6 codes for the mitochondrial GPAT and acl-4 and acl-5 code
for the GPAT expressed in the ER. Testing the lf mutants of these genes for
ethanol responses would help in determining if phospholipid synthesis and its
downstream pathways affect ethanol response phenotypes. Also, testing the
levels of FFA in these acs mutants would be a simple first step in determining
if the effects of ACS lf on ethanol response phenotypes is due to an increase
in levels of FFA. This would allow us to also examine the specific chain-length
of FFA that is increased in these mutants, which could reveal the substratespecificity of the different acs genes in C. elegans.

3.5 Carnitine Palmitoyl Transferases (CPT)
The carnitine shuttle transports long chain acyl CoA across the mitochondrial
membrane, by reversibly converting it to acyl carnitine. cpt-1 codes for CPTI
which is localized in the outer mitochondrial membrane and conjugates
activated long-chain FA with carnitine to form acyl carnitine, which is then
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transported across the inner plasma membrane by Carnitine-acylcarnitine
translocase (CACT). CPTII (gene, cpt-2) converts the acyl carnitine to fatty
acyl CoA by the addition of coenzyme A. CPTI in mammals has three tissuespecific isoforms, CPT1A which is expressed in the liver, CPTIB, expressed in
the muscle, and CPTIC, which is expressed in the brain (Sharma & Black,
2009). I tested C. elegans mutants of three (cpt-3, cpt-4 and cpt-6) of the six
known cpt genes, and Dr. Alaimo, as part of his thesis project, performed
RNAi for two of the other cpt genes (cpt-2 and cpt-5).

The 2x backcrossed cpt-6 mutant strain, and the cpt-2 and cpt-5 RNAi-fed
worms were not significantly different from the WT worms in their ethanol
responses. Though behavioral assays of the 2x backcrossed cpt-3 and cpt-4 lf
mutants did not show a statistically significant difference in initial sensitivity
and AFT compared to WT, considering the high error on these assays and the
trend towards reduced AFT seen in both mutants, we decided to backcross
these to 6x and test them again. The 6x backcrossed mutant of cpt-3 did not
show a significant difference in its ethanol responses compared to WT worms
and the 6x backcrossed mutant of cpt-4 had higher AFT development
compared to WT, but did not differ significantly from WT in terms of initial
sensitivity.

Lack of CPT function would disrupt the entry of long-chain acyl CoA into the
matrix thus halting mitochondrial beta-oxidation of these FA, and also leading
to a buildup of cytosolic acyl CoA that cannot be transported into the
mitochondria. Based on the behavioral assay results from the lf mutants and

75

Dr. Alaimo’s data, it appears that only lf of cpt-4 affects ethanol responses.
This implies that either cpt-4 function in mitochondrial beta-oxidation is
unique, and not compensated for by other cpt genes or that cpt-4 has some
other function (apart from transport of fatty acyl CoA into the mitochondria)
that has an effect on AFT in response to ethanol.

I also performed RNAi for W03F9.4, a C. elegans gene predicted to have
carnitine O-octanoyltransferase function, which in humans has been shown to
be involved in transport of long and medium-chain acyl CoA from the
peroxisomes to mitochondria and cytosol. This gene was included for testing
due to its orthology to CPT1A (from DIOPT), but the W03F9.4 RNAi-fed
worms did not show a significantly different ethanol responses compared to
L4440. In case of RNAi, a positive result (significant phenotype) observed is
considered as evidence for the importance of that gene in modulating the
phenotype. However, failure to observe a phenotype (like in the case of
RNAi–mediated knockdown of W03F9.4, cpt-2 and cpt-5) does not mean that
those genes do not have an effect on ethanol responses, and the results of
this need to be confirmed with lf mutants. Also, it would be interesting to see if
cpt-1, the cpt gene in C. elegans that we did not assay, could play a role in
regulating ethanol responses.

3.6 Acyl CoA dehydrogenases (ACDH)
ACDHs catalyze the first dehydrogenation step in beta-oxidation within the
mitochondria, converting acyl CoA to trans-2-enoyl CoA and require FAD as a
co-factor to perform their function. As discussed in the Introduction, human
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ACADs in the mitochondria are grouped into short, medium and long-chain
enzymes based on their substrate chain-length specificity.

I tested 10 of the 12 acdh genes for a role in ethanol responses, using lf
mutants for six acdh genes (acdh-1, acdh-2, acdh-5, acdh-6, acdh-7 and
acdh-11) and RNAi-mediated knockdown for the other four (acdh-4, acdh-8,
acdh-10 and acdh-12). Five of these ten genes showed significantly different
ethanol responses phenotype compared to WT. Grouping these genes by
their substrate-specificity, we see that, lf in the two short-chain acdh genes,
acdh-1 and acdh-2 leads to ethanol resistance, but has no effect on AFT. Two
of the three medium-chain acdh genes, acdh-7 and acdh-10, have reduced
AFT, and acdh-10 also exhibits a decrease in sensitivity. The other mediumchain enzyme, acdh-8, did not appear to have an effect on ethanol responses
based on RNAi knockdown. All three of the long-chain specific ACDH enzyme
genes, acdh-5, acdh-6 and acdh-11 did not show difference in their ethanol
responses, while RNAi of acdh-12, that catalyzes dehydrogenation of very
long-chain acyl CoAs, showed decreased sensitivity but no effect on AFT.

Lf of ACDH would be predicted to prevent the formation of trans-2-enoyl CoA
and result in accumulation of acyl CoA inside the mitochondria. This would
also be predicted to alter the cellular ratio of FAD/FADH2, and there would be
decreased entry of FADH2 into the ETC. This would disrupt the energy
production from ETC in the form of ATP (FADH2 provides energy required for
the synthesis of 2 ATP molecules through the ETC), ultimately resulting in
decreased ATP production. There is not much information available on this
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class of enzymes apart from their role in mitochondrial beta-oxidation and
associated metabolic diseases, hence it is difficult to hypothesize about which
of the above events could most likely contribute to the ethanol response
phenotypes being observed in these mutants. The FAD/FADH2 ratio in these
acdh mutants can be determined using fluorescence based assays.
Comparing the ratio of FAD/FADH2 between the acdh mutants displaying
altered ethanol response phenotypes and the ones displaying WT-like ethanol
responses could help us determine if this ratio is important in altering neuronal
responses to ethanol in C. elegans. If the FAD/FADH2 ratio correlates with the
ethanol response phenotypes in the acdh mutants, the next step would be to
examine the effect of the ETC on neuronal responses to ethanol since the
FADH2 molecules (released during this reaction) enter the ETC to produce
energy.

3.7 Enoyl CoA Hydratases (ECH)
ECH catalyze the hydration of trans-2-enoyl CoA to form 3-hydroxy acyl CoA
and in higher eukaryotes, the activity of ECH and the other two downstream
enzymes HACD and KAT are carried out by a MTP for oxidation of long-chain
FA. The C. elegans ech family of genes consists of seven members, of which
I have tested three (ech-1.1 using RNAi and ech-1.2 and ech-7 using lf
mutants) and Dr. Alaimo tested the roles of four genes using RNAi (ech-1.2,
ech-2, ech-4 and ech-6). I tested a lf mutant of ech-1.2, though Dr. Alaimo
had performed an RNAi knockdown of this gene and showed that it did not
have a significant effect on ethanol response phenotypes, since the lack of
phenotype seen by RNAi is not reliable. In C. elegans, to determine the
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effectiveness of RNAi, (Kamath et al., 2003) compared the RNAi phenotypes
to phenotypes of know lf mutants and found that while the false positive rate
was <1%, the rate of false negatives was substantially higher, 30%. Possible
reasons for this high false negative rate could be variation in RNAi feeding
protocol, certain genes are more sensitive to RNAi feeding than others and
that some phenotypes exhibit low penetrance, meaning that the phenotype is
expressed in some worms in a population and not in others (Kamath et al.,
2001). Therefore, such cases where we see no significant phenotype through
RNAi feeding need to be confirmed with a lf mutant, when possible. Another
way to confirm this would be to use overexpression of the enzyme to see if
that exhibits a significant ethanol response behavior. The effectiveness of
RNAi could be determined by qRT-PCR, before contemplating the use of lf or
gf mutants.

RNAi knockdown of ech-1.1 and ech-1.2 (performed by Dr. Alaimo) did not
show significantly different ethanol responses compared to WT, but the 2x
backcrossed lf mutant of ech-1.2 showed a significantly reduced AFT, so we
backcrossed this mutant 6x and confirmed this phenotype. Also lf in ech-7
caused reduced AFT. On the other hand, RNAi knockdown of ech-6 showed
an increase in AFT. The initial sensitivity in all these three cases was similar
to WT.

Loss of ECH function would result in trans-2-enoyl CoA accumulation and a
halt in the progression of mitochondrial beta-oxidation. In C. elegans, ech-1.1
and ech-1.2 are the two orthologs of HADHA, the alpha-subunit of the
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mitochondrial trifunctional protein, which exhibits ECH/long-chain HADH
activity. ech-6 and ech-7 are orthologous to the ECHS1, which catalyzes
hydration of short-chain FA. This suggests that a disruption of ECH enzymes
that act on both long-chain and short-chain FA has an effect on ethanol
responses. All three of the ech genes appear to affect only the AFT
component of ethanol response and not the initial sensitivity. Also, the change
in AFT in ech-6 and ech-7 lf are in opposite directions, which is probably not
due to chain-length specificity since both of these are orthologs of the shortchain ECH. While ech-6 localizes to the mitochondria, the information on
subcellular or tissue-specific expression of ech-7 in C. elegans is not
available. One possibility is that the expression pattern could explain the
difference in direction of AFT between these two strains.

3.8 Hydroxy acyl CoA dehydrogenases (HACD/HADH)
These are oxidoreductases, which catalyze the oxidation of 3-hydroxy acyl
CoA to 3-keto acyl CoA and this reaction is coupled with the reduction of
NAD+ to NADH. I examined a lf mutant of hacd-1, the only ortholog of the
human HADH in C. elegans, and found that there was no effect on ethanol
responses due to loss of hacd-1 function. Since ech-1.2 and ech-1.1 are
orthologs of the MTP, they are also predicted to be involved in this step of the
pathway.

Among the consequences of disrupting of this step in beta-oxidation would be
predicted to be an increase in the concentration of 3-hydroxy acyl CoA and
alteration in the ratio of NADH/NAD+. This ratio has shown to be involved in
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the allosteric regulation of beta-oxidation, i.e., increase in the NADH/NAD+
ratio has shown to inhibit beta-oxidation. Three independent studies (Grunnet
& Kondrup, 1986; Lieber, 1994; Reitz, 1979) showed that ethanol metabolism
(into acetate and acetaldehyde) alters the NADH/NAD+ ratio, which inhibits
HADH activity and thus decreases the level of mitochondrial beta-oxidation.
Adachi & Ishii (2002) in their study of rat-cultured hepatocytes showed that
acute ethanol exposure increased superoxide generation in the mitochondria,
which they hypothesized was due to an increase in the NADH/NAD+ ratio and
thus an induction of mitochondrial dysfunction. However, there is not much
literature that could clarify a role for this altered ratio in neuronal response to
ethanol. Based on our analysis of these two genes, it is possible that
disruption of this step in beta-oxidation could be significant in terms of FA and
ethanol metabolism, but with this limited evidence, and ech-1.2 potentially
being involved in both steps of beta-oxidation, the reason for its effect on
modulating behavioral responses to ethanol could be multifold. For example,
ratio of NADH/NAD+ is essential for metabolic pathways like glycolysis,
gluconeogenesis, TCA cycle and FA synthesis. This ratio is also important for
cell signaling and transcriptional regulation, since the enzymes involved in
these processes require NAD+ and NADH for their functions. Therefore,
altered ethanol responses observed in the ech-1.2 mutant could be due to
disruption in any one or a combination of these pathways and enzymes.
Measuring the NADH/NAD+ ratio in the ech-1.2 mutants could help us narrow
down the possible mechanism of altered ethanol response. This ratio can be
measured using commercially available fluorescence detection based
NAD+/NADH assay kits.
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3.9 Keto-acyl CoA Thiolases
The two enzymes primarily involved in this pathway are KAT and ACAT. KAT
catalyzes degradation of a broad range of 3-keto acyl CoA chain lengths to
form an acyl CoA shortened by two carbons (acyl CoA (n-2)) and acetyl CoA.
ACAT specifically catalyzes the last round of degradation in beta-oxidation,
i.e., degradation of acetoacetyl CoA. In C. elegans, I studied two genes to
look at the importance of this step in ethanol response. kat-1 is predicted to
encode mitochondrial KAT and acaa-2 is an ortholog of the human ACAT.
While kat-1 loss of function did not show difference in ethanol responses
compared to WT, acaa-2 lf mutants showed decreased sensitivity to ethanol
and in both mutants, the AFT is similar to WT worms.

Loss of function of enzymes catalyzing the last step of mitochondrial betaoxidation that generates an acetyl CoA and an acyl CoA shortened by two
carbons would be predicted to prevent release of acetyl CoA into downstream
pathways like ketone body synthesis, the glyoxylate cycle, the TCA cycle and
de novo FA synthesis. It would also lead to increase in 3-keto acyl CoA levels
in the mitochondria. Lack of kat-1 functioning in beta-oxidation does not
appear to affect neuronal response to ethanol and one possible reason for
this is that kat-1, though predicted to be involved in mitochondrial betaoxidation (KEGG), is orthologous to ACAT1, a thiolase that is involved in
breakdown of isoleucine and ketone bodies, and has not been implicated in
mitochondrial beta-oxidation. A likely explanation for the decreased sensitivity
seen in acaa-2 lf mutants is that acetyl CoA release into one or more of its
downstream pathways is important for ethanol response. acaa-2 specifically
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catalyzes the last round of beta-oxidation, and there is no further reentry of
shortened acyl CoA into another round of oxidation and the only end-product
of this reaction is acetyl CoA. Since acetyl CoA has several roles in various
pathways of energy metabolism, it is difficult to predict which one of these
could be important for ethanol response.

Acetyl CoA is also utilized in cholinergic neurons for the synthesis of
acetylcholine (Szutowicz et al., 2000). Several studies in humans and mouse
models of alcohol-associated behavior have implicated neuronal nAChRs as
potential targets of alcohol, though the exact mechanism and specific subunits
of these receptors involved are not clear yet (Hendrickson et al., 2013; Tang &
Liao, 2013). It would be interesting to see if the ethanol response phenotype
seen in acaa-2 mutants is due to decrease in availability of acetyl CoA for
acetylcholine synthesis, which could be connected to potential changes in
ethanol interaction with nAChRs. A preliminary experiment that could help
explore this direction would be to express acaa-2 in only the neurons
expressing nAChRs (using pacr-2, promoter of acr-2 that is expressed
specifically in these neurons), in acaa-2 deficient background. We could test
ethanol responses of these worms to see if this rescues the phenotype. If
acaa-2 lf is modifying ethanol sensitivity solely through decrease in
acetylcholine synthesis, the expression of acaa-2 in the nAChR-expressing
neurons should be able to restore WT initial sensitivity. But, if the initial
sensitivity in these mutants is rescued to a certain extent (i.e., sensitivity is
higher than acaa-2 lf but also significantly lower than WT), it suggests that
acetylcholine synthesis is one of the mechanisms through which acaa-2 lf is
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acting on sensitivity to ethanol and there are other mechanisms that
contribute to this phenotype. Apart from acetylcholine synthesis, acetyl CoA is
also involved in other metabolic pathways such as FA synthesis, which could
be a mechanism through which the ethanol response phenotypes in the acaa2 mutants are being altered.

3.10 Conclusion
We tested various genes in the mitochondrial beta-oxidation pathway and saw
that of the 34 genes we examined (including Dr. Alaimo’s data), loss of
function of 13 genes showed a significant effect on ethanol response
phenotype in C. elegans. Looking at the ethanol response phenotypes of lf
mutants of all genes across enzyme families, it is clear that initial sensitivity to
ethanol is affected in a higher number of mutants (in either direction),
compared to AFT. Based on our experiments, we conclude that mitochondrial
beta-oxidation of FA is essential for ethanol response behavior in C. elegans.
However, considering the various roles of the substrate, intermediate
metabolites and end product of beta-oxidation within and outside the
mitochondria, it is difficult to hypothesize a single mechanism of the effect of
these genes on neuronal response to ethanol. There are certain aspects of
this pathway that seem to be particularly important, like FFA, acyl CoA and its
derivatives, ratio of NADH/NAD+ and acetyl CoA. These components have
been implicated in previous research on alcohol and its targets. It is likely that
the effects of loss-of-function of the beta-oxidation enzymes are caused
through more than one mechanism or compound that acts independently or
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interacts with other pathways or compounds to influence ethanol response
phenotypes.

As discussed in this chapter, there is abundant scope for dissecting the role of
individual genes identified through this project in the various downstream
pathways of beta-oxidation and its intermediate products. This project lays the
groundwork for further research on these candidate genes to test the possible
and most likely mechanisms of their action on ethanol responses.
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APPENDICES
APPENDIX I

1. DNA Isolation for PCR
•

Obtain a plate with full of adults, on the verge of starvation (more cells = more
DNA)

•

Label a 1.5 mL eppendorf tube with strain name and “DNA” and date/initials

•

Use pure ddH2O (2 pumps of 850 mL = 1,700 mL) to wash plate

•

Decant and place in 1.5 mL Epp. tube

•

Centrifuge at highest speed for 30 seconds

•

Set pipetter to 1,000 L

•

Decant all of the supernatant and discard

•

Add one mL of ddH2O

•

Spin in centrifuge again for one min

•

Remove all of the waste until there is only 0.1 mL left. Disturb pellet with a
shake

•

Freeze in a -80 C freezer for 15 min (lysing step) (At this point the DNA can
potentially stay in the freezer for a while, so this is an appropriate stopping
point if you are too busy to finish.)

•

Set up the 95 C heat block and the 60 C water bath

•

Make a master mix of lysis buffer (refer to pg.121 for components of lysis
buffer) and Proteinase K (12 L Proteinase K/1,000 L lysis buffer)

•

Add 1/3 of the solution in tubes (100 L in tube = 33 X # of tubes + some for
the PCR fairies)
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o Example: 35μL Lysis Buffer X 5 DNA samples = 175, so 175 L is the total
volume of Lysis Buffer
o Add 180 L of Lysis Buffer to the master mix tube
o 175 Lysis Buffer X 12/1,000 = 2.1 L Proteinase K (10 mg/mL)
o Add the Pro K to the master mix tube and vortex to mix well.
o Add 33 L of master mix to each of your DNA samples.
•

Incubate at 60 C (the functional temperature of Proteinase K) Stick all tubes
in a “floatie”, swirl, and let sit for about 90 min.

•

Incubate at 95 C to inactivate Proteinase K for 20 min. (use heat block)

•

When saving excel data, enter name of strain, conc., and time point

•

Store DNA tubes in -20 C incubator

2. DNA Isolation for SWPCR
•

Add 5μL of 10 mg/mL Proteinase K to 95μL of lysis buffer in a 1.5mL
eppendorf tube

•

Add 3μL of mix to 0.2mL PCR tubes

•

Pick 1-5 worms and place them into the solution

•

Place the tubes in the -80 C incubator for at least 20 minutes

•

Heat the tubes at 60 C for 60 minutes

•

Heat the tubes at 95 C for 15 minutes

•

Tap or spin the tubes to get the condensation to the bottom of the tube

•

The lysate can be used for PCR or can be stored in the -20 C incubator

3. Standard PCR protocol
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Note: All PCR is to be done on ice or in a cold storage box. Never leave out
primers, enzymes, or DNA, as this will ruin it!

•

Dilute all primers to be used. Stock powdered primers are diluted in TE buffer
unless they are to be used by the sequencing center. The sequencing center
prefers all primers to be diluted in ddH20. The primers come with an
information sheet detailing how much water or buffer is required to bring the
primer up to 100 uM. Then make a personal dilution with 90 uL of ddH 20 and
10 uL of the stock primer in a labeled 1.5 mL eppendorf tube.

•

The next step is to create the PCR master mix. Label a 1.5 mL eppendorf
tube with the pair of primers to be used, one tube per pair of primers. Always
set up extra reaction mixtures because there is always loss via pipetting. Add
the following per reaction:

o ddH2O

6.7 uL

o Reaction Buffer

1.0 uL

o dNTP

0.2 uL

o DreamTaq

0.1 uL

o Forward Primer

0.5 uL

o Reverse Primer

0.5 uL

•

Vortex the master mix to ensure contents are thoroughly mixed. Aliquot 9.0 uL
of master mix to each of the PCR tubes. Then add 1.0 uL of DNA to each of
the reaction tubes. If you desire to increase or decrease the amount of DNA
used, be sure to alter the volume of water accordingly in the master mix. The
total volume should always be 10 uL.
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•

If using the strips of tubes place all the caps on. If using a plate then affix the
adhesive film securely on. Use the speedball to help securely fasten the film.

•

Put the strips or plate into the thermal cycler.

•

Select the “mapping program”:

o 94 pause
o 94 2 minutes
o 94 15 seconds
o 58 45 seconds

35 cycles

o 72 1 minute
o 72 5 minutes
•

Store PCR products at -20 C.

4. Single Worm PCR (SWPCR) protocol
•

Prepare a master mix in a 1.5 mL eppendorf tube (must be used immediately)

o Add the following per reaction (taking into account the PCR fairies):
ddH2O

13.4 μL

Reaction Buffer 2.00 μL
dNTP

0.40 μL

DreamTaq

0.20 μL

Forward Primer 1.00 μL
Reverse Primer 1.00 μL
•

Aliquot 18μL of master mix to each PCR tube

•

Place in a thermocycler (times, temperatures and cycles between dotted lines
may vary):

o Select the “mapping program”:
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94 pause
94 2 minutes
94 15 seconds
58 45 seconds

35 cycles

72 1 minute
72 5 minutes
•

Store PCR products at -20°C.

5. GENEWIZ Guidelines for sample preparation for Sanger Sequencing
(using Purified PCR Template)
•

Label your tubes on the side with your initials and sample number.

•

Dilute your sequencing primer (forward/reverse) to 5 µM (pmol/µl) using
water. You will need 5 µl for each sequencing reaction.

•

For the amount of template needed for PreMixed sample, please refer to the
table below. Prepare template in 10 µl for each sequencing reaction. Please
make dilutions in water or Tris. For best results, do not use Tris-EDTA (TE)
because EDTA will inhibit the sequencing reaction.

•

In the same tube, mix template (10 µl) and your primer (5 µl)
according to the table below.
Table 12. Concentration of DNA template and primer used for Purified PCR products in Sanger
sequencing sample preparation
DNA Type
DNA/Product
Template
Template
Total Your
Primer Premixed
Length
Concentration in Mass
Total Picomoles Volume*
10 µl
(Template +
Your Primer)
Purified
<500 bp
~1 ng / µl
~10 ng
25 pmol
15 µl
PCR
500 - 1000 bp
~2 ng / µl
~20 ng
Products
1000 - 2000 bp
~4 ng / µl
~40 ng
2000 - 4000 bp
~6 ng / µl
~60 ng
> 4000 bp
Treat as plasmid Treat as plasmid
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6. RNAi Protocols
a. Making RNAi Cultures from Frozen Stock
1.) Turn on shaker and set at 37 C
2.) Make LB/AMP solution
▪

Take a bottle of LB (50 mL)

▪

Add 50 ug/mL of ampicillin

•

50 mL x 50 ug/mL = 2500 ug = 0.0025g

▪

Vortex bottle for 30 seconds

3.) Aliquot 5 mL of LB/AMP solution into 15 mL falcon tubes and label with gene
name and date
4.) Go to the -80 and take out frozen stock culture
5.) Using the P2.5 with tip attached scrape frozen culture a few times to cover tip
6.) Eject tip into falcon tube
7.) Place tubes in the shaker at 37 C for 8-12 hours

b. Freezing RNAi Cultures
•

Properly label (Formal name of gene, Gene name – if available, Library it
came from, Date, Initals) 1.8 mL cryo tube vials

•

Note: you should have 1 tube for the -80 C freezer and 1 tube to be placed in
the nitrogen tank

•

Pipette

300

uL

of

glycerol

into

the

cryo

tubes

(Glycerol is very viscous so be sure to wait and make sure the correct amount
is pipetted into your tip and expelled into the cyro tube)
•

Add 1.5 mL of inoculated RNAi culture into the cyro tube with glycerol, pipette
up and down until mixed evenly
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OR
•

Add 1.5 mL of inoculated RNAi culture into the cyro tube with glycerol.

•

Using an inoculation loop, flame loop

•

Immerse loop into inoculated RNAi culture

•

Then transfer loop, inoculating the culture in the cryo tube

•

Pipette inoculated culture and glycerol mixture up and down until
evenly mixed

•

Place

tubes

into

the

-80 C

c. Preparing Ampicillin (+tetracycline) Plates for RNAi
•

250 mL LB

•

4.0g bacto-agar

•

- Autoclave -

•

Place in 60C water for ~20minutes then add:

•

250uL 50mg/mL Ampicillin

•

(167uL 15mg/mL tetracycline)

•

Pours ~25 medium plates

d. Carbinacillin Plates for RNAi
The following will make about 60 plates, which is equivalent to 0.75L.
1. 0.722 L dH20
2. 2.25 g NaCl
3. 12.0 g Bacto-Agar
4. 1.875 g Bacto-Peptone
5. Swirl flask
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freezer

6. Autoclave for 90 minutes under liquid cycle (usually takes 2 hours)
7. Let cool for 30 minutes at room temperature
8. 0.75 mL of MgSO4 (1M)
9. 0.75 mL CaCl2 (1M)
10. 0.75 mL Cholesterol (5 mg/mL)
11. 18.75 mL KP04 (1M)
12. 0.1875 mL Carbenicillin (100 mg/mL)
13. 7.50 mL IPTG (0.1 M)

Why we use these numbers
For steps 8 – 11:
We want a final concentration of 1 mM (0.001M) for each of these
components.
C1 = 1M
V1 = X
C2 = 0.001M
V1 = 750 mL

We have solutions that are at a 1 M concentration and we want to know how
much of that solution do we need to add to give use a 0.001 M concentration
of this solution in the total volume (750 mL) of our sample. X = 0.75 mL

For step 10:
We want a final concentration of 25 ug/mL (0.025 mg/mL).
C1 = 100 mg/mL
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V1 = X
C2 = 0.025 mg/mL
V2 = 750 mL

We have the antibiotic that is at a concentration of 100 mg/mL. This is a
standard concentration the lab makes. However, if you are ever using a
different antibiotic, it is important to check the bottle or the manufactures
website on how to suspend the chemical. I obtained 0.025 mg/mL final
concentration of the antibiotic solution in the total volume (750 mL) of our
sample.

For Step 13:
IPTG is our inducer for the vector/plasmid that is carrying the clone of our
gene. The inducer allows for the initiation of the expression of the gene in the
bacteria. The bacteria will produce a dsRNA and the worms eat the colonies
on the plate allowing the dsRNA to be introduced to their system. dsRNA is
obtained by allowing transcription in both directions of the plasmid rather than
in one direction, which would just generate one strand that would not produce
a knockdown of the gene. Once the dsRNA is in the system, the Dicer
enzyme will breakdown the structure into smaller interfering RNA fragments
called siRNAs (22 n.t.). The fragments are incorporated into a multicomponent
nuclease, called RNA-induced silencing complex (RISC) and becomes
activated with ATP. RISC then unwinds the siRNAs and uses them as a guide
for substrate selection for the endogenous mRNA of the gene. Activated RISC
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complexes can regulate gene expression at many levels. Such complexes act
by promoting RNA degradation and translation inhibition.

We want a final concentration of 1 mM (.001 M) for IPTG. In this case IPTG is
recommended to be stored in a 0.1 M concentration. We have 0.1 M solution
of IPTG but need to add X amount of this solution to end up with a final IPTG
concentration of 0.001 M in 750 mL. X = 7.50 mL

Making solutions:
Carbenicillin:
1.) Weigh out 100 mg
2.) Add to tube
3.) Bring the volume up to 1 mL
4.) Vortex

IPTG
M.W. = 238.3 g
1 Molar solution = 238.3 g / 1L
0.1 Molar solution = 1.20 g / 50 mL
1.) Weigh out 1.20 g
2.) Add to tube
3.) Bring volume up to 50 mL
4.) Vortex
5.) Aliquot out into smaller volumes
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It is important to note, that if you are changing the amount of plates you need,
you have to redo the calculations. For example, Steps 8-12 need to be
subtracted from the total volume you what to give you the amount of water to
add. Usually we will add some chemical and bring it up to volume to make
some concentrated solution. This is the only case where we don’t account for
dry contents such as steps 2-4, but it is important to get the concentrations
right of the chemicals that matter.

e. Plasmid DNA extraction using Invitrogen PureLink HQ Mini Plasmid
Purification Kit
Preparing Lysate
•

Prepare the Resuspension Solution with RNase A. Resuspend the lyophilized
RNase A (12 mg) in 200 μl of Resuspension Solution, and then add the
resuspended mixture to the remaining Resuspension Solution for a final
concentration of 0.1 mg/ml RNase A. After mixing, Resuspension Solution
should be stored at 4°C.

•

Prepare the Wash Buffer with ethanol. Add 64 ml of 96–100% ethanol to the
entire volume of Wash Buffer (16 ml).

•

Check the Neutralization Buffer and Lysis Buffer before use for salt
precipitate. If present, place each buffer in a 37°C water bath for 5 minutes
until the salts redissolve and the solution clears. Do not shake the Lysis
Buffer, as this can lead to foaming.

Preparing Cell Lysate
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•

In a microcentrifuge tube, pellet 1–3 ml (1–2 × 109) of E. coli cells from
overnight cultures by centrifugation in a tabletop centrifuge at 1,500 × g for 15
minutes.

•

Completely resuspend the pellet in 240 μl of Resuspension Solution, prepared
with RNase A as described above.

•

Add 240 μl of Lysis Buffer to the above solution. Mix gently by inverting the
tube 4–8 times.

•

Incubate for 3–5 minutes at room temperature. Do not exceed 5 minutes.

•

Add 340 μl of Neutralization/Binding Buffer, and mix gently by inverting the
tube 4–8 times.

•

Centrifuge for 10 minutes at maximum speed in a tabletop centrifuge to clarify
the cell lysate.

•

Proceed to Binding DNA.

Binding DNA
•

Place a PureLinkTM spin column inside a 2 ml collection tube.

•

Pipette or decant the supernatant from step 6, previous page, into the spin
column.

•

Centrifuge the column at room temperature at 10,000–14,000 × g for

•

1 minute. Discard the flowthrough, and place the column back in the tube.

•

If loading multiple samples on the same column (up to 1.5 × 1010 cells),
repeat Steps 2–3 for each lysate.

•

Add 650 μl of Wash Buffer, prepared with ethanol as described on the
previous page, to the column.

•

Centrifuge the column at room temperature at 10,000–14,000 × g for
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•

1 minute. Discard the flowthrough from the collection tube, and place the
column back in the tube.

•

Centrifuge the column at maximum speed for 1–3 minutes to remove the
residual wash buffer.

•

Proceed to Eluting DNA.

Eluting DNA
•

Place the spin column in a clean 1.7 ml elution tube. Add Elution Buffer or
sterile, distilled water as specified below

•

· Add 50 μl of Elution Buffer or water to the center of the column if the
expected DNA yield is <30 μg.

•

· Add 100 μl of Elution Buffer or water to the center of the column if the
expected DNA yield is >30 μg.

•

Incubate the column at room temperature for 1 minute, then centrifuge at
maximum speed for 1 minute.

•

The elution tube contains your purified DNA. Remove and discard the column.

f. GENEWIZ– Guidelines for sample preparation for Sanger Sequencing
(using Plasmid DNA Template)
•

Label your tubes on the side with your initials and sample number.

•

Dilute your sequencing primer (forward/reverse) to 5 µM (pmol/µl) using
water. You will need 5 µl for each sequencing reaction.

•

For the amount of template needed for PreMixed sample, please refer to the
table below. Prepare template in 10 µl for each sequencing reaction. Please
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make dilutions in water or Tris. For best results, do not use Tris-EDTA (TE)
because EDTA will inhibit the sequencing reaction.
•

In the same tube, mix template (10 µl) and your primer (5 µl)
according to the table below.

Table 13. Concentration of DNA template and primer used for Plasmid DNA template in Sanger
sequencing sample preparation
DNA Type
DNA Length
Template
Template
Total Your
Primer Premixed
(include vector)
Concentration in Mass
Total Picomoles Volume*
10 µl
(Template +
Your Primer)
Plasmids
<6 kb
~50 ng / µl
~500 ng
25 pmol
15 µl
6 - 10 kb
~80 ng / µl
~800 ng
> 10 kb
~100 ng / µl
~1000 ng

7. Ethanol Assay with Copper Rings
•

Dry NGM plates with the lids removed in the 37°C incubator for two hours.

•

Remove the plates and allow them to equilibrate to room temperature for
about 15 minutes, evaporation will continue to occur.

•

Weigh each plate and record the weight on the side of the plate.

•

Heat the copper rings and melt them into the surface of the agar, be careful to
not touch the hot forceps to the agar. Tap the rings with the forceps to make
sure the ring is melted completely into the agar. If the ring is not completely in
the agar then the worms will be able to crawl out. Four rings maximum per
plate.

•

Using the available ethanol table select the correct concentration and the
weight of your plate and add that much ethanol to your assay plate. Be sure to
save an equal number of plates with rings and no ethanol for starvation
plates.
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•

Record the weights of your plates and the amount of ethanol added in your
laboratory notebook.

•

Allow the ethanol to equilibrate for approximately 2 hours

•

After the ethanol has equilibrated move your animals into their rings and
remove all food by gently scraping it off with your pick. Be sure to flame in
between rings to avoid transferring worms of one strain into a ring of worms of
a different strain.

•

Allow the worms to starve for 30 minutes. This minimizes the food left on their
bodies.

•

Transfer the worms from the starvation plates onto the assay plates. This
transfer must be as speedy as possible to ensure accurate data, aim for less
than 2 minutes per plate. Parafilm the plates after the worms have all been
transferred and start a timer.

•

Depending on the type of assay you may need to observe your assay plates
or you may need to track your worms using the computer and camera rig.

8. Computer Tracking and Analyzing Movies
a. Taking movies:
•

Open Image-Pro Plus 6.0

•

Turn on the camera and the light source

•

Click on “Acquire” at the tope of the Image Pro window

•

Select “Video/Digital Capture”

•

The window that pops up on the right half of the screen (labeled “QImaging
Digital Camera”) will have information regarding different camera settings.
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The settings already in place should be the ones most commonly used unless
Jill or Andrew says otherwise.
•

Click on “Preview” at the top left corner of the QImaging Digital Camera
window.

•

Place ringed plate on the light source at the base of the microscope using the
“Live Preview” window to put all rings in the camera’s field of view. Also use
the preview window to adjust the lab light source to the proper brightness to
take a clear image.

•

Click on “Snap” at the top left corner of the QImaging Digital Camera window,
and save the image (as a .seq file) to designated folder.

b. Analyzing movies:
•

Open Image-Pro Plus 6.0

•

Click on “File” and select “Open” to load video saved in a designated file

•

Click on “Macro” heading at the top of the Image-Pro window and select

•

“flatten_magnify_add_ring”

•

Drag the white ring that appears over to the ring of worms to analyze, and
adjust the white ring to fit the shape of the copper ring

•

Click on “Measure” heading at the top of the Image-Pro window and select
“Track Objects”

•

Click on the track objects automatically icon (yellow lightning bolt icon on top
right side of the “Tracking Data Table” window

•

Three smaller windows will pop up. On “Count/Size” window click on “Select
Ranges” and adjust vertical line to adjust brightness in order to outline each
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worm, but without making the background appear too bright. Close window
when properly adjusted.
•

Use “Sequencer Toolbar” to select the movie frame that captures the most
number of worms in the selected ring.

•

Click on “Count” in the Count/Size window, and then click on “Continue” in the
Tracking window.

•

Two sets of boxes with questions will pop up. For the first box that pops up
click on “Yes,” and for the second window that pops up click on “No.”

•

A list of tracks with speeds will appear in the Tracking Data Table window.
Click on tracks making sure they accurately records paths of worms, deleting
tracks that are recording miscellaneous objects (using blue X to delete
selected track).

•

Once true worm tracks are remaining, open up an Excel file, and click on the
green Excel icon at the top right of the Tracking Data Table window to import
list of tracks and speeds to Excel. Because mean speed is the information of
interest, on a separate worksheet on the Excel file, make a table for the mean
speeds for each strain of worms for each time point recorded.

•

****Make sure to make a new worksheet before importing the tables for each
ring. Otherwise, the table will import over the previously imported table.

9. Recipes
S Basal (400 mL)
•

8 mL 5 M NaCl

•

20 mL 1 M KPO4 (pH 6)

•

372 mL dH2O
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- Post Autoclave •

400 μL 5 mg/mL cholesterol

M9 (1 Liter)
•

6 g Na2HPO4

•

3 g KH2PO4

•

5 g NaCl

•

1 mL of 1M MgSO4

- Autoclave -

Freezing Solution (1 Liter)
•

18 mL 5 M NaCl (Must be heated and swirled vigorously)

•

50 mL 1 M KPO4 (pH 6)

•

300 mL DMSO

•

632 mL dH2O

•

129 mL 0.05 M K2HPO4

•

871 mL 0.05 M KH2PO4

•

5.85 g NaCl

S Buffer (1L)

- Autoclave -

4X Lysis Buffer (100 mL)
•

1.491 g KCl

•

0.4856 g Tris

•

0.2033 g MgCl2

•

0.04 g Gelatin
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•

1.8 mL NP4O

•

1.8 mL Tween-20

- Autoclave (Filter)-

1L KPO4 (pH 6.0) in H2O
•

110.26g KH2PO4

•

33.064g K2HPO4

2.5 mM dNTP
•

2.5 μL of each of the 4 dNTPs

•

90 μL ddH20

LB
•

1 Tablet per 50 mL H2O

-

Autoclave (same day) -

Cholesterol
•

5 mg/mL in 95% EtOH

-

Filter Sterilize -

Proteinase K
•

10 mg/mL in H2O
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APPENDIX II
Table 14. Primers for PCR of mutant C. elegans strains obtained from Caenorhabditis Genetics Center
website.
Annealing
Strain
Genotype
Forward Primer(s)
Reverse Primer(s)
temperature
(°C)
69.6
CTGTTTCAGGCAAATTGGGT
TTCCTGTGCTCAAGTCGTTG
(out)
(out)
acs-4
VC2240
(ok2872)
ATGTTTGGGAACTCGACAGC
ATCCTTGAACAACAGGGCAG
69.6
(in)
(in)
AACAACACGTTGCTGGAGTG
CCACCCATGGCCTAACTCTA
Not used
(out)
(out)
acs-5
RB2015
(ok2668)
TCTAATCGAGTTGGATTCACG
TGCAATTACAGGGTCAACCA
64
(in)
(in)
GGTCGATTCTTCGATTTCCA
TGGGGAGCATAGGTTTTTCA
Not used
(out)
(out)
acs-17
RB1377
(ok1562)
CCTAAAACATATGGCCACCG
TGAACGCACGGTATGTTTGT
64
(in)
(in)
GTCACCTCAAACCAAGGGAA
GGTGGGATGTACGGTAGGAG
62
(out)
(out)
acdh-1
VC1087
(ok1514)
CTTCAGCAATATTCCAGCCC
AACGGAAGGCGAATCAATTA
64
(in)
(in)
AAGCTCAATGGCTTTTTCCA
CGTTTTTCTGCCAAGCTTTC
64
(out)
(out)
hacd-1
RB2101
(ok2776)
CAGAAATTTTCCCCCACAAA
CAGCGACCAATTTGTCCATAA
64
(in)
(in)
TTCGTGAAGCATATTGCGAG
GCCCCTTGATAGTGATTCCA
Not used
(out)
(out)
acaa-2
RB1606
(ok1978)
GTATTGTGCGCCCAACTTCT
64
CCATTTCCTATTTTCCCCGT (in)
(in)
CAGTCTATCGCAATGTCGGA
GGAGTTGACGATTCGGAGAC
63.5
(out)
(out)
T02G5.7
RB2566
(ok3574)
CCGAGGATCTTTCGCTAACTT
Not used
TTTCCGAAAACGCTCACTG (in)
(in)
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Table 15. Primers for PCR of mutant C. elegans strains designed on NCBI Primer-BLAST

Strain

Genotype

Forward Primer(s)

Reverse Primer(s)

VC40812

acs-3
(gk826522)
acs-5
(ok2668)
acs-13
(ok2861)

TCCTTAGCTCACATCTATGAGC

GTTAAAAAACGTCTGCAGTTTCC

CCCAGATAGTGTCACGACCG
(within deletion)
TGAACAAATGATTGAGCGACA
(out)
CGACACATTCCGTTTGACCG (in)

GAGCAGCTCACTCACTGGAC
(within deletion)
ACCGATGAGCTCAAAACGAC
(out)
GGCTCACATGCTCGAGAGAG
(in)
AAGTGAAATGAGCCGAGAGGG

67.2

63.5

TACTCTTCCAGGAACGGGCT

AGAATGATAAGAGGTGATGTGA
ACC
TCGACATTAGGCAATTTTGGCA

ACATGGCTTCTTTGGGTTGTC

CACCACAACATCACTCACGTTC

63.5

TCCTGCACGCATTCCAAGAT (out)

69.6

RB2015
RB2147

VC20634
VC20616
VC40798
VC40360
VC20502

acs-22
(gk364606)
cpt-3
(gk356297)
cpt-4
(gk818803)
cpt-6
(gk594576)
acdh-2
(gk143151)

TGTCGTCAAGGATGGAACGG
GAAACAAACCCGAAGACAACTG

VC40929
VC40288
VC40665
VC41029
VC40235
QC119
VC2462
VS24

63.5
Not used
69.6

66

acdh-5
(gk907299)
acdh-6
(gk886629)
acdh-7
(gk556025)
acdh-11
(gk753061)
F54D5.7
(gk936057)
ech-1.2
(gk527451)
ech-7 (et6)

GAACTTGGAAGAATAACTTCCAGG

CCTACAAGGCGACCTACACC
(out)
TTCTCAACGGATCAAAACGG
(in_WT nucleotide at SNP)
TTCTCAACGGATCAAAACGA
(in_mutant nucleotide at SNP)
GTGTGTGTGCACAGCTGATA

TCAGGCACAACACAAAAGTCG

CTCACCAAATTGTGCAAGAGCA

63.5

CGGGAAAGCATATTTAACCTGC

TCACTCTTCCAGGTTGACG

63.5

CGTTGAGACCAGGTACCGTAT

GTCATAGCCATCGGACAGGA

66

GTGGAACGAGTCGATTCGGGA

ACTTTTCCCTCATCTTTCAGGCG

63.5

TTTGGGTACCTCCAGCTCCT

AGATGTTGCCGTGGTGAAGA

63.5

TGTGCTTACATCGGCCCTAC

CATCTAGGCAGACAGGCAGG

66

T02G5.4
(ok3160)
kat-1
(tm1037)

GCATTCCAATTTTTCCAGGTCTGT

GCTCCTCCATGTGGGTTCAC

63.5

GTCTCTCATTCATCTCGATCCG
(out)
AGGAGGCGAGTGTGTTCTTT
(within deletion)

AACTGCTTCCTGTGAGGCAA
(out)
ATAAGCATCGGTCAGTCCGTC
(within deletion)

63.5

CCTGAAAGTTTTACAC (in)

VC40973

Annealing
temperature
(°C)
63.5
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Table 16. Restriction enzymes and digest conditions used for snipSNP genotype detection
Strain
Genotype
SNP (WT/Variant)
Restriction site
Restriction
Restriction Digest Conditions
sequence
enzyme

VC20634

acs-22
(gk364606)

C/T

5′…T▼CGA…3′

Incubation

Inactivation

TaqI

65 °C (4hr)

80 °C (20
minutes)

DdeI

37 °C (4hr)

65 °C (20
minutes)

Hpy188I

37 °C (4hr)

65 °C (20
minutes)

HaeIII

37 °C (4hr)

80 °C (20
minutes)

BseYI

37 °C (4hr)

80 °C (20
minutes)

MfeI

37 °C (4hr)

No
inactivation

3′…AGC▲T…5′
VC40812

acs-3
(gk826522)

T/A

5′…C▼TNAG…3′
3′…GANT▲C…5′

VC20616

cpt-3
(gk356297)

C/T

5′…ACN▼GT…3′
3′…TG▲NCA…5′

VC40360

cpt-6
(gk594576)

C/T

5′…GG▼CC…3′
3′…CC▲GG…5′

VC41029

F54D5.7
(gk936057)

G/A

VC40798

cpt-4
(gk818803)

G/C

5′…C▼CCAGC…3′
3′…GGGTC▲G…5
′
5′…C▼AATTG…3′
3′…GTTAA▲C…5′

Table 17. RNAi plasmid DNA concentrations quantified using NanoDrop
Gene name

Gene name (in RNAi library)

acs-16
W03F9.4
acdh-4
acdh-8
acdh-10
acdh-12
ech-1.1
B0303.3

F47G6.2
W03F9.4
T10E9.9
K05F1.3
T08G2.3
E04F6.5
C29F3.1
B0303.3

DNA Concentration
(ng/μL)
74.8
28.9
91
24.4
22.5
49.9
34.9
32.3
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Table 18. 100% Ethanol volumes for various plate weights for specific final concentrations of ethanol (in
mM).
Plate weight Agar
50
100
150
200
250
300
350
400
450
(g)
Vol
(ml)
17.9
10.0
30.1
60.2
90.3
120.4
145.5
180.7
206.8
232.9
262.0
17.8
9.9
29.8
59.6
89.4
119.3
144.1
178.9
204.7
230.6
259.4
17.7
9.8
29.5
59.0
88.6
118.1
142.7
177.1
202.7
228.3
256.8
17.6
9.7
29.2
58.4
87.7
116.9
141.3
175.3
200.7
226.0
254.3
17.5
9.6
28.9
57.9
86.8
115.7
139.8
173.6
198.6
223.7
251.7
17.4
9.5
28.6
57.3
85.9
114.5
138.4
171.8
196.6
221.4
249.1
17.3
9.4
28.3
56.7
85.0
113.4
137.0
170.0
194.6
219.2
246.5
17.2
9.3
28.0
56.1
84.1
112.2
135.5
168.3
192.6
216.9
244.0
17.1
9.2
27.7
55.5
83.2
111.0
134.1
166.5
190.5
214.6
241.4
17.0
9.2
27.5
54.9
82.4
109.8
132.7
164.7
188.5
212.3
238.8
16.9
9.1
27.2
54.3
81.5
108.6
131.3
162.9
186.5
210.0
236.3
16.8
9.0
26.9
53.7
80.6
107.4
129.8
161.2
184.5
207.7
233.7
16.7
8.9
26.6
53.1
79.7
106.3
128.4
159.4
182.4
205.4
231.1
16.6
8.8
26.3
52.5
78.8
105.1
127.0
157.6
180.4
203.2
228.6
16.5
8.7
26.0
52.0
77.9
103.9
125.5
155.9
178.4
200.9
226.0
16.4
8.6
25.7
51.4
77.0
102.7
124.1
154.1
176.3
198.6
223.4
16.3
8.5
25.4
50.8
76.2
101.5
122.7
152.3
174.3
196.3
220.8
16.2
8.4
25.1
50.2
75.3
100.4
121.3
150.5
172.3
194.0
218.3
16.1
8.3
24.8
49.6
74.4
99.2
119.8
148.8
170.3
191.7
215.7
16.0
8.2
24.5
49.0
73.5
98.0
118.4
147.0
168.2
189.5
213.1
15.9
8.1
24.2
48.4
72.6
96.8
117.0
145.2
166.2
187.2
210.6
15.8
8.0
23.9
47.8
71.7
95.6
115.6
143.4
164.2
184.9
208.0
15.7
7.9
23.6
47.2
70.8
94.5
114.1
141.7
162.1
182.6
205.4
15.6
7.8
23.3
46.6
70.0
93.3
112.7
139.9
160.1
180.3
202.9
15.5
7.7
23.0
46.0
69.1
92.1
111.3
138.1
158.1
178.0
200.3
15.4
7.6
22.7
45.5
68.2
90.9
109.8
136.4
156.1
175.8
197.7
15.3
7.5
22.4
44.9
67.3
89.7
108.4
134.6
154.0
173.5
195.2
15.2
7.4
22.1
44.3
66.4
88.5
107.0
132.8
152.0
171.2
192.6
15.1
7.3
21.8
43.7
65.5
87.4
105.6
131.0
150.0
168.9
190.0
15.0
7.2
21.5
43.1
64.6
86.2
104.1
129.3
147.9
166.6
187.4
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500
291.1
288.2
285.4
282.5
279.7
276.8
273.9
271.1
268.2
265.4
262.5
259.7
256.8
254.0
251.1
248.2
245.4
242.5
239.7
236.8
234.0
231.1
228.3
225.4
222.5
219.7
216.8
214.0
211.1
208.3

Table 19. Average basal speeds of 2x backcrossed mutant strains at 0mM ethanol concentration at
two different time points (10 minutes and 30 minutes after being transferred to the assay plate)
Genotype

Number of assays

acs-3(gk826522)
acs-4(ok2872)
acs-5(ok2668)
acs-13(ok2861)
acs-17(ok1562)
acs-22(gk364606)
cpt-3(gk356297)
cpt-4(gk818803)
cpt-6(gk594576)
acdh-1(ok1514)
acdh-2(gk143151)
acdh-5(gk907299)
acdh-6(gk886629)
acdh-7(gk556025)
acdh-11(gk753061)
F54D5.7(gk936057)
ech-1.2(gk527451)
hacd-1(ok2776)
T02G5.4(ok3160)
T02G5.7(ok3574)
acaa-2(ok1978)

6
5
6
6
6
6
8
8
6
5
6
6
6
5
6
6
8
6
5
6
6

Average speed (μm/s)
at 0mM (10 minutes)
177.14
178.28
138.99
183.71
222.56
163.51
164.42
197.20
177.41
144.56
168.21
203.16
192.58
165.92
196.31
156.83
189.90
189.65
169.56
170.32
211.28

Average speed (μm/s)
at 0mM (30 minutes)
161.03
171.06
119.65
173.99
213.14
166.90
173.25
190.09
187.07
155.14
161.27
198.63
195.61
173.96
192.36
177.66
188.60
187.49
165.47
173.06
214.60

Table 20. Average basal speeds of 6x backcrossed mutant strains at 0mM ethanol concentration at
two different time points (10 minutes and 30 minutes after being transferred to the assay plate)
Genotype

Number of assays

acs-3(gk826522)
acs-4(ok2872)
acs-5(ok2668)
acs-13(ok2861)
acs-22(gk364606)
cpt-3(gk356297)
cpt-4(gk818803)
acdh-1(ok1514)
acdh-2(gk143151)
acdh-7(gk556025)
ech-1.2(gk527451)
T02G5.4(ok3160)
acaa-2(ok1978)
ech-7(et6)
kat-1(tm1037)

6
6
6
6
6
6
6
6
6
6
6
6
6
6
6

Average speed (μm/s)
at 0mM (10 minutes)
108.53
130.99
124.63
200.30
178.62
203.25
188.81
139.50
173.58
169.38
67.90
198.62
220.67
188.48
173.86
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Average speed (μm/s)
at 0mM (30 minutes)
110.71
140.57
117.14
187.15
165.34
210.77
183.07
142.72
179.21
177.73
58.06
194.25
219.10
195.41
171.21

Table 21. Average basal speeds of RNAi-mediated knockdown worms at 0mM ethanol
concentration at two different time points (10 minutes and 30 minutes after being transferred to the
assay plate)
Genotype

Number of assays

W03F9.4 (RNAi)
acdh-4 (RNAi)
acdh-8 (RNAi)
acdh-10 (RNAi)
acdh-12 (RNAi)
ech-1.1 (RNAi)
B0303.3 (RNAi)

8
8
8
8
8
8
8

Average speed (μm/s)
at 0mM (10 minutes)
215.73
212.82
208.47
205.54
209.97
220.20
216.41
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Average speed (μm/s)
at 0mM (30 minutes)
209.00
200.93
193.41
196.66
195.93
209.62
198.93

APPENDIX III
1. Graphs of ethanol response phenotypes of 2x backcrossed mutants of
candidate genes in the mitochondrial beta-oxidation pathway

Figure 11. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-3 lf mutant. At 400mM exogenous ethanol these mutants
displayed increased initial sensitivity and reduced development of AFT
relative to N2 (n = 4)
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Figure 12. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-4 lf mutant. At 400mM exogenous ethanol these mutants
displayed increased initial sensitivity but no significant difference in
development of AFT relative to N2 (n = 6)
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Figure 13. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-5 lf mutant. At 400mM exogenous ethanol these mutants
displayed increased initial sensitivity and no significant development of AFT
relative to N2 (n = 6).
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Figure 14. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-13 lf mutant. At 400mM exogenous ethanol these mutants
displayed decreased initial sensitivity and no significant difference in the
development of AFT relative to N2 (n = 4)
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Figure 15. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-17 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 6)
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Figure 16. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acs-22 lf mutant. At 400mM exogenous ethanol these mutants
displayed reduced development of AFT, but not significantly different initial
sensitivity relative to N2 (n = 6)
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Figure 17. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed cpt-3 lf mutant. At 400mM exogenous ethanol these mutants did
not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 8)
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Figure 18. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed cpt-4 lf mutant. At 400mM exogenous ethanol these mutants did
not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 8)
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Figure 19. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed cpt-6 lf mutant. At 400mM exogenous ethanol these mutants did
not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 4)
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Figure 20. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed ech-1.2 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity but showed
reduced development of AFT compared to N2 (n = 8)
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Figure 21. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed F54D5.7 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 4)
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Figure 22. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-1 lf mutant. At 400mM exogenous ethanol these mutants
had significantly increased sensitivity but did not differ significantly from N2 in
terms of their AFT development (n = 5)
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Figure 23. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-2 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity but displayed
significantly reduced AFT development (n = 6)
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Figure 24. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-5 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 5)
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Figure 25. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-6 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 5)
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Figure 26. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-7 lf mutant. At 400mM exogenous ethanol these mutants
displayed significantly decreased initial sensitivity and had reduced
development of AFT relative to N2 (n = 5)
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Figure 27. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acdh-11 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 5)
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Figure 28. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed hacd-1 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 6)
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Figure 29. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed T02G5.4 lf mutant. At 400mM exogenous ethanol these mutants
showed significantly decreased initial sensitivity but they did not differ from N2
in terms of AFT development (n = 5)
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n=6

Figure 30. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed T02G5.7 lf mutant. At 400mM exogenous ethanol these mutants
did not differ significantly from N2 in terms of initial sensitivity and AFT
development (n = 6)
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Figure 31. Ethanol sensitivity and acute functional tolerance (AFT) of 2x
backcrossed acaa-2 lf mutant. At 400mM exogenous ethanol these mutants
showed a significantly decreased initial sensitivity than N2 but did not differ
significantly from N2 in terms of AFT development (n = 6)
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2. Graphs of ethanol response phenotypes of 6x backcrossed mutants of
candidate genes in the mitochondrial beta-oxidation pathway

Figure 32. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acs-5 lf mutant. At 400mM exogenous ethanol these mutants
displayed increased initial sensitivity and reduced development of AFT
relative to N2 (n = 6).
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Figure 33. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acs-13 lf mutant. At 400mM exogenous ethanol these mutants
displayed decreased initial sensitivity, but no significant difference in the
development of AFT relative to N2 (n = 6).

147

Figure 34. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acs-22 lf mutant. At 400mM exogenous ethanol these mutants
did not show any significant difference in terms of initial sensitivity or AFT
relative to N2 (n = 6).
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Figure 35. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed cpt-3 lf mutant. At 400mM exogenous ethanol these mutants did
not show any significant difference in terms of initial sensitivity or AFT relative
to N2 (n = 6).
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Figure 36. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acdh-1 lf mutant. At 400mM exogenous ethanol these mutants
displayed significantly decreased sensitivity compared to N2, but did not show
any significant difference in terms of AFT development relative to N2 (n = 6).
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Figure 37. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acdh-2 lf mutant. At 400mM exogenous ethanol these mutants
displayed significantly decreased sensitivity compared to N2, but did not show
any significant difference in terms of AFT development relative to N2 (n = 6).

151

Figure 38. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acdh-7 lf mutant. At 400mM exogenous ethanol these mutants
did not show any significant difference in terms of initial sensitivity but
displayed significantly reduced AFT development relative to N2 (n = 6).
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Figure 39. Ethanol sensitivity and acute functional tolerance (AFT) of 10x
backcrossed ech-7 lf mutant (without paqr-2 deletion). At 400mM exogenous
ethanol these mutants did not show any significant difference in terms of initial
sensitivity but displayed significantly reduced AFT development relative to N2
(n = 6).
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Figure 40. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed T02G5.4 lf mutant. At 400mM exogenous ethanol these mutants
did not show any significant difference in terms of initial sensitivity or AFT
development relative to N2 (n = 6).
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Figure 41. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed acaa-2 lf mutant. At 400mM exogenous ethanol these mutants
had significantly decreased initial sensitivity compared to N2 but did not show
any significant difference in terms of AFT development relative to N2 (n = 6).

155

Figure 42. Ethanol sensitivity and acute functional tolerance (AFT) of 6x
backcrossed kat-1 lf mutant. At 400mM exogenous ethanol these mutants did
not show any significant difference in terms of initial sensitivity or AFT
development relative to N2 (n = 6).
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3. Graphs of ethanol response phenotypes of RNAi-mediated knockdown of
candidate genes in the mitochondrial beta-oxidation pathway

Figure 43. Ethanol sensitivity and acute functional tolerance (AFT) of
W03F9.4 RNAi knockdown of C. elegans. At 400mM exogenous ethanol
these worms did not show any significant difference in terms of initial
sensitivity or AFT development relative to L4440 (n = 8).
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Figure 44. Ethanol sensitivity and acute functional tolerance (AFT) of acdh-4
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
did not show any significant difference in terms of initial sensitivity or AFT
development relative to L4440 (n = 8).
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Figure 45. Ethanol sensitivity and acute functional tolerance (AFT) of acdh-8
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
did not show any significant difference in terms of initial sensitivity or AFT
development relative to L4440 (n = 8).
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Figure 46. Ethanol sensitivity and acute functional tolerance (AFT) of acdh-10
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
showed a significantly decreased sensitivity to ethanol and reduced AFT
development compared to L4440 (n = 8).
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Figure 47. Ethanol sensitivity and acute functional tolerance (AFT) of acdh-12
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
showed a significantly decreased sensitivity to ethanol but no significant
difference in development of AFT relative to L4440 (n = 8).
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Figure 48. Ethanol sensitivity and acute functional tolerance (AFT) of ech-1.1
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
did not show any significant difference in terms of initial sensitivity or AFT
development relative to L4440 (n = 8).
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Figure 49. Ethanol sensitivity and acute functional tolerance (AFT) of B0303.3
RNAi knockdown of C. elegans. At 400mM exogenous ethanol these worms
did not show any significant difference in terms of initial sensitivity or AFT
development relative to L4440 (n = 8).
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